Progressive models of Parkinson's disease : behavioural and neurochemical analyses by Alvarsson, Alexandra
From Department of Clinical Neuroscience 
Karolinska Institutet, Stockholm, Sweden 
PROGRESSIVE MODELS OF 
PARKINSON'S DISEASE: BEHAVIOURAL 
AND NEUROCHEMICAL ANALYSES 
Alexandra Alvarsson 
 
Stockholm 2015 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2015 
© Alexandra Alvarsson, 2015 
ISBN 978-91-7676-020-8 
Progressive Models of Parkinson's Disease: Behavioural 
and Neurochemical Analyses 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Alexandra Alvarsson 
Principal Supervisor: 
Professor Per Svenningsson 
Karolinska Institutet 
Department of Clinical Neuroscience 
Center for Molecular Medicine 
Division of Translational Neuropharmacology 
 
Co-supervisors: 
Professor Thomas Perlmann 
Karolinska Institutet 
Department of Cell and Molecular Biology 
Ludwig Institute for Cancer Research 
 
Associate professor Per Andrén 
Uppsala University 
Department of Pharmaceutical Biosciences 
Division of Medical Mass Spectrometry 
 
Dr. Nicoletta Schintu 
Karolinska Institutet 
Department of Clinical Neuroscience 
Center for Molecular Medicine 
Division of Translational Neuropharmacology 
 
Opponent: 
Professor Raul R. Gainetdinov 
Italian Institute of Technology  
Department of Neuroscience and Brain 
Technologies 
Skolkovo Institute of Science and Technology 
St. Petersburg State University 
Faculty of Biology  
Institute of Translational Biomedicine 
 
Examination Board: 
Associate professor Kent Jardemark  
Karolinska Institutet   
Department of Physiology and Pharmacology 
 
Associate professor Rochellys Diaz Heijtz 
Karolinska Institutet  
Department of Neuroscience 
 
Professor Hans Nissbrandt 
University of Gothenburg  
Department of Pharmacology 
 
 
 
  
 
 
 
To my family with love 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Just because you can explain it doesn't mean it's not still a miracle.” 
― Sir Terry Pratchett  
  
ABSTRACT 
Parkinson’s disease (PD) is a common neurodegenerative disorder diagnosed based on the 
presence of motor symptoms, including resting tremor, postural impairment, bradykinesia 
and rigidity. The pathological hallmarks are degeneration of midbrain dopaminergic neurons 
and the accumulation of inclusions containing the misfolded protein α-synuclein (termed 
“Lewy bodies”) throughout the nervous system. However, when the cardinal motor 
symptoms of PD emerge already 60-80% of the dopaminergic content has been lost, meaning 
that patients get diagnosed with PD at a very late disease stage. PD is also associated with 
many non-motor symptoms, which can appear up to 30 years before the onset of the motor 
symptoms. In order to fully appreciate the aetiology of PD, including mechanisms underlying 
the earliest pathological events, valid model systems are needed. Thus, the work of this thesis 
has focused on the characterization and utilization of progressive models of PD, including the 
cNurr1
DATCreER
 knock-out (KO) model (studies I and II), the Lmx1a/b
DATCre
 KO model (study 
III), and a viral vector-induced model overexpressing α-synuclein in the ventral tegmental 
area (VTA) (study IV), allowing investigation of the early pathological stages of PD.   
We here report that the cNurr1
DATCreER
 model recapitulated early pathological features of PD, 
including a progressively reduced expression of several dopaminergic markers in the striatum 
and ventral midbrain, reduced striatal levels of dopamine and its metabolites, a dopamine 
fiber pathology not accompanied by midbrain dopaminergic cell death, and profound motor 
symptoms. cNurr1
DATCreER
 KO animals also displayed enhanced corticostriatal glutamate 
release compared with wild-type animals. The PD-related features observed in the 
cNurr1
DATCreER
 model were likely caused by an altered expression of mitochondrial genes, in 
line with mitochondrial dysfunction being a pathological mechanism proposed in human PD. 
Using this model in combination with the well-established 6-OHDA lesioned mouse model 
and trace amine-associated receptor 1 (TAAR1) KO mice, a potentially therapeutic role of 
TAAR1 was revealed in experimental Parkinsonism and L-DOPA-induced side effects. 
Ablation of developmental transcription factors Lmx1a and Lmx1b in dopaminergic neurons 
induced an early progressive striatal pathology resembling key aspects of PD. Lmx1a/b 
ablation also impaired both motor functions and non-motor functions, including olfactory and 
short-term memory functions, but left anxiety- or depressive-like behaviours intact. 
Moreover, Lmx1b was required for the normal function of the autophagic-lysosomal 
pathway, and, importantly, it was also decreased in midbrain dopaminergic neurons of 
patients with PD. These findings point toward a clinically relevant role of Lmx1b in human 
PD, suggesting that its pathological mechanism is related to impaired degradation of 
defective proteins, which has been proposed as a pathological mechanism in PD. 
Further focusing on the non-motor symptoms of PD, α-synuclein was overexpressed in the rat 
VTA using adeno-associated viral vectors. The VTA contains dopaminergic neurons 
projecting to the prefrontal cortex and to limbic regions. Our findings revealed a role of the 
dopaminergic projections of the VTA in emotional long-term memory, which was vulnerable 
to α-synuclein pathology. This effect was likely mediated via its innervations to limbic 
regions including the amygdala, hippocampus and nucleus accumbens.  
In conclusion, we here show how both pathological and behavioural Parkinson-like features 
related to early PD can be induced by ablation of transcription factors Nurr1 and Lmx1a/b, 
and by overexpression of α-synuclein in VTA. Our experiments also highlight the usefulness 
of the cNurr1
DATCreER
 KO model as a bilateral model of early PD, and reveal a role of 
TAAR1 in experimental PD. Hopefully these data will contribute to a better understanding of 
the early disease stages of PD and ultimately to the development of better treatment 
regiments. 
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1 INTRODUCTION 
Parkinson’s disease (PD) is a common, slowly progressive neurodegenerative disorder with a 
pathogenesis that remains largely unknown. It affects 1-2% of the population over 65 years of 
age. PD is clinically diagnosed based on motor dysfunctions, and pathologically defined by a 
prominent loss of dopamine synthesizing neurons in the substantia nigra pars compacta (SNc) 
projecting to the striatum (Lees et al., 2009). A pathological hallmark of PD is the presence of 
inclusions partially formed by the protein α-synuclein (Lewy bodies) (Braak and Del Tredici, 
2008; Braak et al., 2004; Braak et al., 2003). A progressive accumulation of Lewy bodies 
throughout the central, peripheral, and enteric nervous systems correlate with the 
development of clinical signs (Braak and Del Tredici, 2008). Most cases of PD are sporadic 
without any heritability, however, over ten PD genes, including α-synuclein mutations or 
duplications, have been identified. Pathological studies in postmortem brain samples from 
end-stage PD patients are characterized by a profound loss of mesencephalic dopaminergic 
neurons (mDA), above all in the SNc, but also in the ventral tegmental area (VTA) which 
projects to many limbic regions. Consistently, the cardinal motor symptoms of PD are often 
preceded by non-motor symptoms, including depression, anosmia, REM sleep disorders, 
obstipation and mild cognitive impairments (Schrag, 2004). When the motor symptoms 
appear, up to 80% of mDA neurons have already degenerated (Hornykiewicz and Kish, 
1987; Riederer and Wuketich, 1976; Tissingh et al., 1998; Tissingh et al., 1998), indicating 
that these symptoms appear very late in the disease process. The golden standard treatment 
in PD is dopamine replacement by its precursor L-DOPA. However, clinical fluctuations, 
dyskinesias, hallucinations and exaggerated debilitating reward seeking are complications of 
long-term treatment with L-DOPA (Dunnett and Björklund, 1999). Furthermore, there is 
currently no treatment that halts or slows the neurodegenerative processes in PD. An 
increased understanding of the earliest pathological events in PD is key to develop more 
efficient treatments, and especially to target the neurodegenerative process. To this end, it is 
also vital to discover biomarkers to detect PD at an earlier disease stage than what is possible 
today. 
1.1 SYMPTOMATOLOGY OF PARKINSON’S DISEASE 
1.1.1 Motor symptoms 
The earliest descriptions of symptoms resembling Parkinsonism were described as early as 
1000 BC in ancient Indian and Chinese writings (Goetz, 2011). The first medical description 
of PD, referred to as “paralysis agitans” or “shaking palsy”, was published by Dr. James 
Parkinson in 1817. This description was later refined by Jean-Martin Charcot in 1872 (Goetz, 
2011), who also suggested the term “Parkinson's disease” to name the disorder. This 
renaming was based on Charcot’s observation that neither tremor nor weakness affect all 
patients with PD, as the name “shaking palsy” might suggest  (Goetz, 2011). The four 
cardinal symptoms of PD include bradykinesia (slowness of movement), muscular rigidity, 
resting tremor, and postural and gait impairments (Kalia and Lang, 2015). The 
symptomatology of PD is heterogeneous, and two major subtypes have been described based 
on the motor symptomatology: tremor-dominant PD and non-tremor dominant (akinetic-
rigid) PD, which have been proposed to  have different aetiologies (Marras and Lang, 2013). 
Tremor-dominant PD is often associated with a slower disease progression and a less 
debilitating symptomatology compared with non-tremor dominant PD (Kalia and Lang, 
2015). The motor symptoms become more severe as PD progresses. Current PD medications 
(dopamine agonists or dopamine replacement therapy by L-DOPA), are effective in 
managing the motor symptoms of PD during the early disease phase. However, the 
emergence of severe side-effects associated with prolonged L-DOPA treatment, including 
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dyskinesia, psychosis and clinical fluctuations (“on” and “off” periods, fluctuations between 
responding well and poorly to L-DOPA) (Hely et al., 2005), complicate the management of 
PD. Moreover, since the diagnosis of PD today is based solely on the motor symptoms of PD, 
which appear during the later stages of the disease progression, when 60-80% of the striatal 
dopaminergic content has already been lost (Hornykiewicz and Kish, 1987; Riederer and 
Wuketich, 1976; Tissingh et al., 1998a; 1998b), there is a call to identify biomarkers for 
earlier disease stages. This would allow an earlier diagnosis as well as the use of early 
therapeutic interventions to slow or reverse the disease progression.  
1.1.2 Non-motor symptoms 
When James Parkinson first described PD in 1819 he defined it as a fundamental motor 
disorder, but he also recognized an array of non-motor symptoms, including sleep 
dysfunctions, autonomous nervous system dysfunctions (dysautonomia) and 
neuropsychiatric symptoms (Parkinson, 1817). These symptoms are often described as 
equally or even more debilitating than the motor symptoms by the patients (Chaudhuri et 
al., 2010; Schrag et al., 2000), and are often not responsive to antiparkinsonian medications. 
However, up until today these symptoms are poorly recognized in the clinic and/or often 
remain undeclared by PD patients themselves (Chaudhuri et al., 2010; Shulman et al., 
2002). Non-motor symptoms can appear early during the pathology, often before the onset 
of the cardinal motor symptoms. This is called the premotor, or prodromal, phase of PD. 
The non-motor symptoms of PD commonly include constipation, loss of olfaction, sleep 
disturbances, anxiety and depression (Abbott et al., 2003; Iranzo et al., 2006; Shiba et al., 
2000; Tolosa et al., 2007), and can be divided into distinct neuroanatomical manifestations 
(Lee and Koh, 2015), as shown in Table 1.1. Notably, these symptoms are not restricted to 
the central nervous system. Dysfunctions of the autonomic nervous system can precede the 
motor symptoms by many years, are very common during the early disease stages and 
progress in severity throughout the course of the disease (Tolosa et al., 2007).  
Table 1.1 Neuroanatomy of the symptomatology in PD 
Cortical symptoms Psychosis  
Cognitive impairments  
Impulse control impairments 
Basal ganglia symptoms 
 
Apathy  
Restlessness/akathisia (“inability to sit”) 
Brainstem symptoms 
 
Depression  
Anxiety  
Sleep disorders 
Peripheral nervous system symptoms 
 
Constipation  
Pain  
Orthostatic hypotension  
Sensory disturbances 
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Non-motor symptoms are very common in PD. For instance, impaired sense of olfaction 
and odour discrimination affects up to 90% of patients with PD (Hawkes et al., 1997). 
Impaired olfaction, however, is not a symptom restricted to PD, but can also be seen in 
other neurodegenerative disorders including Alzheimer’s disease, rendering olfactory 
impairments less useful as a potential biomarker of PD. Painful sensations have been 
reported in 40-85% of PD patients (Cury et al., 2015), and are often reported also as “off”-
period symptoms (Witjas et al., 2002). Fatigue or daytime sleepiness has been reported in 
40-43% of patients (Hilten et al., 1993; Shulman et al., 2001). Cognitive impairments, 
anxiety and depression are also frequently reported in PD, and have a large impact on the 
patients’ quality of life, as will be discussed further below. 
Moreover, PD patients often experience non-motor fluctuations following prolonged L-
DOPA treatment, characterized by symptoms which appear only during “off” periods, while 
other non-motor symptoms are aggravated during “off” periods (Todorova et al., 2014). 
1.1.2.1 Cognitive impairments and dementia in Parkinson’s disease 
At the end of the nineteenth century mental changes were already being reported in patients 
with PD, including impaired memory, irascibility (short temper), melancholia and dementia. 
Cognitive impairments range in prevalence between 24-46% in patients with PD depending 
on cohort characteristics (Aarsland et al., 2010; Foltynie et al., 2004; Muslimovic et al., 
2005). Today there is an increasing awareness that mild cognitive impairments are present 
also in newly diagnosed patients with PD (Foltynie et al., 2004; Muslimovic et al., 2005). 
However, mild cognitive impairments are also associated with an older age at disease onset, 
increased disease duration, more severe motor symptoms and a more advanced disease state 
in PD (Aarsland et al., 2010). Moreover, PD patients who also suffer from depression more 
often present with cognitive impairments compared with non-depressed subjects (Aarsland et 
al., 2010).  
The most common cognitive impairments in PD involve executive, psychomotor and 
memory functions (Elgh et al., 2009; Muslimovic et al., 2005), apathy and decreased levels of 
motivation (den Brok et al., 2015). Mild cognitive impairments have a significant impact on 
the patients’ quality of life and health outcomes (Lawson et al., 2014a, 2014b), particularly 
because these symptoms can progress to overt dementia, which is a strong predictor of the 
need for nursing home placement (Aarsland et al., 2000). A systematical review by Aarsland 
and colleagues, using strict inclusion and exclusion criterions for PD samples, revealed a 
31.3% prevalence of dementia in PD patients (Aarsland et al., 2005). However, after 20 years 
of disease duration dementia can affect up to 83% of PD patients (Hely et al., 2008). Both 
cortical Lewy bodies and Alzheimer-like pathological changes have been reported to 
contribute to the manifestation of dementia in PD, whereas the pathology related to mild 
cognitive impairments in PD is less known, mainly because patients usually survive until 
these symptoms develop into dementia (Aarsland et al., 2011a). However, evidence point 
towards cognitive impairments being related to similar, albeit milder, pathological changes as 
dementia in PD (Aarsland et al., 2011a). Pathological studies in postmortem brain samples 
from PD patients with dementia revealed a Lewy body density 5 times higher in cortical areas 
compared with non-demented patients with PD (Apaydin et al., 2002; Hurtig et al., 2000). 
Lewy bodies are also found in brainstem nuclei, including the noradrenergic locus coeruleus 
and the serotonergic raphe nuclei, limbic structures, cholinergic forebrain neurons, and in the 
cerebral cortex (Emre, 2004). In general, antiparkinsonian medications targeting the 
dopaminergic system have both beneficial and deleterious effects on cognitive tasks, 
depending on which brain circuitries are involved in the specific task (Cools et al., 2001).  
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1.1.2.2 Depression and anxiety in Parkinson’s disease 
The prevalence of depressive symptoms in PD have been reported to range between 35 
and 50% (Aarsland et al., 2011b; Shulman et al., 2001), and have been reported as the main 
determinant of a poor quality of life in PD (Schrag, 2006). Anxiety has been reported in 28-
38% of patients with PD (Menza et al., 1993; Shulman et al., 2001; Stein et al., 1990), and 
has a very high level of comorbidity with depression  (Menza et al., 1993), much higher than 
in depressed patients without PD (Walsh and Bennett, 2001). PD patients do not often 
present with classic major depression, but usually show less self-blame, guilt, sense of 
failure and self-destructive thoughts compared with patients suffering from primary major 
depression (Schrag, 2006). It is also comparatively uncommon that depressed PD patients 
commit suicide. Depression can also occur as an “off” symptom, and is then responsive to 
antiparkinsonian treatments (Menza et al., 1990). Degeneration of the mesolimbic and 
mesocortical dopaminergic pathways, which project from the VTA to limbic and cortical 
structures, are thought to play a pivotal role in depressive symptoms in PD (Lieberman, 
2006). However, depression in PD is thought to be multifactorial and also related to 
changes in the noradrenergic and especially serotonergic systems (Chan-Palay, 1993; 
Kostić et al., 1987; Mayeux et al., 1988, 1984; Menza et al., 1999; Mössner et al., 2001), all 
potentially contributing to the symptomatology. An important observation is that 
pathological changes in the raphe nuclei and locus coeruleus, which harbour serotonergic 
and noradrenergic cell bodies respectively, appear before pathological lesions occur in the 
dopaminergic cell bodies of SNc (Table 1.2). This is consistent with depressive symptoms 
sometimes occurring before the onset of motor symptoms in PD.  
Although traditional antidepressants can be beneficial in the management of depression 
in PD, they are associated with a high variability in treatment outcomes. The general 
understanding of antidepressant treatments has also been hampered by the lack of 
controlled clinical trials evaluating the efficacy in PD. However, the antidepressant 
pramipexole, which targets D3 receptors that are extensively expressed in the limbic 
system, was recently shown to efficiently improve depressive symptoms in PD (Barone, 
2011).  
1.2 TREATMENT OF PARKINSON’S DISEASE 
The current treatment options for PD focus on targeting dopamine depletion and offer only 
symptomatic relief, without slowing the neurodegenerative processes. Thus, better treatment 
options are warranted. An emerging area is the use of non-dopaminergic treatment options in 
the management of PD. Such treatments include anticholinergics, amantadine, MAO 
inhibitors and deep brain stimulation. However, a better understanding of the disease 
processes underlying PD is vital in order to slow, halt, or even reverse the neurodegeneration 
in PD. 
1.2.1.1 L-DOPA 
Dopamine replacement therapy by L-DOPA (L-3,4-dihydroxyphenylalanine, also called 
levodopa) is currently the golden standard and the most efficient treatment for PD, despite its 
disabling side effects. L-DOPA is a precursor of dopamine which, as opposed to dopamine 
itself, can cross the blood-brain barrier. Once L-DOPA has entered the brain it will be 
converted to dopamine by the surviving dopaminergic neurons. In order to prevent L-DOPA 
from being converted to dopamine in the peripheral nervous system, L-DOPA must be co-
administered with a peripheral L-DOPA decarboxylase inhibitor to prevent peripheral side 
effects. 
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In patients suffering from PD, the therapeutic effect of L-DOPA is gradually lost, whereas 
L-DOPA induced dyskinesias, or abnormal involuntary movements, emerge in response to 
previously therapeutic doses of L-DOPA. No antiparkinsonian medications slow the 
progression of PD, and as dopaminergic neurons continue to degenerate, there are 
progressively fewer nigrostriatal dopaminergic terminals that can convert L-DOPA into 
dopamine, store dopamine in synaptic vesicles and subsequently release dopamine. 
Eventually L-DOPA is decarboxylased into dopamine and released by serotonergic neurons, 
which lack inhibitory D2 autoreceptors and thus are unable to properly buffer dopamine levels 
(Carta et al., 2007; Rylander et al., 2010). This results in large fluctuations in extracellular 
dopamine in response to L-DOPA administration, and subsequently to functional pre- and 
postsynaptic changes throughout the basal ganglia. The molecular mechanisms behind the 
emergence of L-DOPA induced dyskinesias are still poorly understood. However, L-DOPA 
induced dyskinesias can be reduced by the weak NMDA receptor antagonist amantadine, 
suggesting that the glutamatergic system is involved (Jenner, 2008). Changes in 
corticostriatal connectivity, which are related to glutamatergic neurotransmission and altered 
density of glutamatergic AMPA and NMDA receptors, have been implicated in the induction 
of dyskinesias (Jenner, 2008). This has been further explored in study II of this thesis. 
1.2.1.2 Dopamine agonists 
Dopamine agonists have fewer side effects and are often used during early disease stages of 
PD to delay the use of L-DOPA and the subsequent onset of L-DOPA induced side effects 
(Kuzel, 1999; Lange, 1998; Montastruc et al., 1999; Pahwa et al., 2004). Although dopamine 
agonists are associated with fewer side effects compared with L-DOPA, they are not as 
efficient as L-DOPA as the disease progresses (Lange, 1998; Montastruc et al., 1999; Pahwa 
et al., 2004). One commonly used dopamine agonist is ropinirole, which acts on D2-like 
receptors (D2, D3 and D4 receptors) with the highest affinity for D3 receptors (Kulisevsky and 
Pagonabarraga, 2010; Pahwa et al., 2004). Ropinirole has been used in study II to investigate 
the modulatory role of dopamine receptors on corticostriatal glutamate release in 
experimental Parkinsonism. 
Apomorphine is a non-selective dopamine agonist that activates both D1-like and D2-like 
dopamine receptors. It has a rapid onset of effect, making it effective in patients 
experiencing both predictable and unpredictable “off” periods, and can also be useful when 
the patient is anticipating an “off” period (Trenkwalder et al., 2015). Subcutaneous 
apomorphine infusions can be useful in the treatment of PD for patients who experience 
troublesome “off” periods with oral medications and who would otherwise need very 
frequent apomorphine injections (Trenkwalder et al., 2015). Apart from being useful in the 
management of motor fluctuations, there is also evidence that apomorphine can have effects 
on non-motor symptoms associated with “off” periods (Trenkwalder et al., 2015). 
Apomorphine is also commonly used to investigate the efficacy of 6-OHDA lesions, which 
are used to induce experimental Parkinsonism in rodents. When apomorphine is injected 
systemically into a hemiparkinsonian rodent with a unilateral 6-OHDA lesion, a 
characteristic rotational behavior is induced, its intensity reflecting the level of 6-OHDA 
induced neurodegeneration. This supersensitive response induced by apomorphine 
treatment is associated with the stimulation of postsynaptic dopamine receptors in the 
denervated hemisphere, which become supersensitized following dopamine denervation, 
causing the animal to rotate contralaterally in response to apomorphine (Creese and Snyder, 
1979; Creese et al., 1977). 
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1.2.1.3 Deep brain stimulation 
PD is associated with increased activity of the SNc and the GPi. Deep brain stimulation 
(DBS) via electrodes targeting the subthalamic nucleus (STN) and the GPi is sometimes 
used to treat advanced treatment-resistant PD and L-DOPA induced dyskinesias, by 
simulating the effects of lesions to these regions reversibly, without destroying the brain 
tissue (Fasano et al., 2012). Although DBS has well-documented therapeutic effects, 
including almost immediate therapeutic effects on tremor, rigidity and bradykinesia 
(Volkmann et al., 2002), the mechanisms of action remain elusive (Kringelbach et al., 
2007).  
1.2.1.4 Immunotherapy 
Abundant evidence has indicated a role of α-synuclein in the neuronal death in PD, and 
even that α-synuclein may propagate the neurodegenerative process in a prion-like manner 
(Visanji et al., 2013).  In light of this, targeting extracellular α-synuclein via immunization-
based therapies has emerged as a potential consideration (Kalia et al., 2015). The results of 
the first clinical trial of a vaccine composed of immunogenic peptides mimicking the C-
terminus of α-synuclein have not yet been published (Kalia et al., 2015).  
1.2.1.5 Stem cell therapy 
The implantation of fetal ventral mesencephalic cells into the brain of patients with PD has 
proven to be beneficial in some patients, but the usefulness of such therapies is limited by 
ethical concerns and the limited availability of donor tissue. Although in vivo animal 
experiments have shown that fetal grafts can survive and integrate into the host striatum, 
release dopamine and restore motor functions (Brundin et al., 1986; Nikkhah et al., 1995), 
human clinical trials have remained inconclusive, with some patients even developing 
severe dystonia and dyskinesia (Luo et al., 2009).  Embryonic stem cells have also been 
proposed in the therapy of PD, and can circumvent the logistic complications associated 
with fetal grafts since they can be grown in vitro. However, undifferentiated embryonic 
stem cells are prone to form tumours in vivo (Luo et al., 2009). The risk of tumourigenesis 
is also a concern when using stem cells that have been differentiated in vitro. The use of 
pluripotent adult stem cells holds more promise for future therapeutic management, since it 
avoids the ethical problems associated with the use of embryonic stem cells. These cells can 
instead be harvested from the central nervous system (CNS) and blood marrow of a 
postmortem donor, or even potentially from the patient itself, and can differentiate into a 
variety of cells in response to growth factors (Luo et al., 2009). The clinical usefulness of 
such stem cell therapies remains to be further explored (Trounson et al., 2011). 
1.2.1.6 Gene therapy 
Gene therapy, performed via the injection of viral vectors that replace or correct a defective 
gene, can potentially be used to treat many disorders by altering the disease environment. In 
the case of PD, this would be done by the induction of genes or transgenes that favour 
neuronal survival in the basal ganglia. Another strategy is to increase the efficacy and 
reduce the side effects of current pharmacological and surgical treatments. One obstacle in 
the treatment of neurological disorders is the blood-brain barrier, which hinders most viral 
vectors to enter the CNS. Adeno-associated virus (AAV) subtype 9 has the ability to cross 
the blood-brain barrier (Duque et al., 2009), making it useful for targeting pathological 
processes of the brain. Many trials have suggested safety and efficacy of gene therapy in 
PD (Bartus et al., 2013), but the majority of phase II experiments have failed to show any 
beneficial effects beyond the placebo effect (Bartus et al., 2013). Whereas studies using 
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Table 1.2 Symptomatology related to pathological stage of PD 
 
Symptom Related brain structures Braak stage 
Olfactory impairments Olfactory bulb,  
Anterior olfactory nucleus 
1 
1 
Constipation Dorsal nucleus of the vagus  1 
Depression, anxiety Locus coeruleus 
Raphe nuclei 
Hippocampus 
2 
2 
4 
Sleep disorders Locus coeruleus 
Pedunculopontine nucleus 
Basal forebrain 
2  
3 
3 
Motor functions Substantia nigra 3 
Apathy, impaired motivation Ventral tegmental area 
Amygdala 
3 
3 
Cognitive dysfunctions, dementia Hippocampus  
Amygdala 
Nucleus basalis 
Frontal cortex 
4 
4 
4 
5 
Adapted from (Braak et al., 2004; Braak et al., 2003; Dickson et al., 2009; Tolosa et al., 2007). 
 
neurotrophic factor GDNF to protect dopaminergic neurons were associated with unwanted 
side effects (Nutt et al., 2003), the failure of gene therapy involving the growth factor 
neurturin was suggested to be associated with the need of earlier delivery, optimally before 
any extensive neurodegenerative damage has occurred (O’Connor and Boulis, 2015). This 
highlights the need for the discovery of biomarkers that would enable an earlier diagnosis 
and thus earlier therapeutic management of PD. 
1.3 PATHOGENESIS OF PARKINSON’S DISEASE 
1.3.1 Lewy bodies and α-synuclein 
PD is characterized by an accumulation of misfolded protein aggregates, containing 
ubiquitin and the insoluble misfolded protein α-synuclein, in vulnerable neurons of the 
enteric, peripheral and central nervous system (Golbe, 1999). These inclusions were first 
described by Fritz Heinrich Lewy in 1912, and were termed “Lewy bodies” by Konstantin 
Nikolaevich Tretiakoff in 1919 (Goedert et al., 2012). Lewy bodies and Lewy neurites 
(when inclusions appear in neuronal processes) do not appear during healthy ageing (Thal 
et al., 2004). In postmortem tissue from patients with PD or prodromal PD, Lewy bodies 
are found throughout the CNS as shown in Table 1.2. Lewy neurites are most numerous in 
the substantia nigra and in the CA2 and CA3 regions of the hippocampus in postmortem 
tissue (Love, 2005). Although Lewy bodies are the most studied pathological feature of PD, 
aggregated α-synuclein is also found in particulate form in cell bodies (Kuusisto et al., 
2003). α-synuclein is enriched at presynaptic terminals, where it, under healthy conditions, 
promotes the assembly of the SNARE machinery required for vesicle fusion, and also 
appears to be protecting nerve terminals against injury (Chandra et al., 2005).  
It is not known why α-synuclein misfolds and aggregates in PD, but several mechanisms, 
including dysfunctional protein folding and degradation have been proposed. The α-
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synuclein protein is normally unfolded, but depending on its environment it can adopt 
partially folded structures as well as monomeric and oligomeric alpha helix and beta sheet 
conformations, or different types of aggregates including amyloid-like fibrils (Uversky, 
2003). Oxidation of dopamine has been shown to affect α-synuclein aggregation in vitro in a 
pH-dependent manner (Pham et al., 2009), which may explain the pronounced vulnerability 
of dopaminergic neurons in PD.  
The role of α-synuclein in the pathological processes of PD has not yet been established. 
It has been suggested that α-synuclein inclusions can interfere with axonal transport (Saha 
et al., 2004) and interrupt neurotransmitter production by reducing the functional levels of 
the rate-limiting enzymes TH and ChAT (Beach et al., 2008; Dugger and Dickson, 2010). 
However, it is also known that nerve cells harbouring Lewy bodies or Lewy neurites can 
survive for decades, which has raised questions on the toxic role of α-synuclein inclusions 
in the pathology of PD. It has even been suggested that α-synuclein inclusions may have a 
neuroprotective role (Lee et al., 2006), although this view is generally considered 
controversial. α-synuclein overexpression experiments have demonstrated that 
dopaminergic neurons are more vulnerable to α-synuclein overexpression compared with 
other neurons, possibly due to the higher iron content and dopamine’s ability to generate 
reactive oxygen species (ROS) which leads to the induction of oxidative stress, a process 
which, in PD, may be further aggravated by mitochondrial dysfunction (Xu et al., 2002). 
However, non-dopaminergic neurons are also known both to present with Lewy bodies and 
to degenerate in PD (Braak et al., 2003). The reduced vulnerability of dopaminergic 
neurons of the VTA in PD compared with dopaminergic neurons of the SNc is not known, 
but has been attributed to a comparatively higher expression of dopamine transporters and 
lower expression of VMAT2 in SNc neurons, which would render these particular neurons 
more susceptible to dopamine-mediated toxicity (Gainetdinov et al., 1998) 
1.3.2 Pathological staging 
The pathological process of PD progresses slowly, and there is extensive evidence that the 
neuronal damage appears before the onset of clinical symptoms and progresses for many 
years before fully manifested (Del Tredici et al., 2002). The topographic spread of the 
neuronal pathology in PD is characteristic and predictive, and, upon autopsy, PD can be 
classified as one of six neuropathological stages based on α-synuclein deposition, called 
Braak stages (Braak et al., 2003) (Table 1.2). During the first stage, lesions are found in the 
dorsal nucleus of the vagus nerve (the tenth cranial nerve projecting from medulla 
oblongata to the heart, lungs and gastrointestinal system) in the brain stem, and in the 
olfactory bulb. During stage 2, the Lewy pathology spreads through the medulla oblongata 
and pontine tegmentum. At stage 3, Lewy bodies spread to the substantia nigra and the 
amygdala, which correlates with the onset of the first motor symptoms, commonly rigidity, 
resting tremor or gait disturbances.  At stage 4, the Lewy pathology has spread to the 
temporal cortex. During subsequent disease stages, 5 and 6, lesions reach the neocortex, 
which is paralleled by cognitive dysfunctions (Braak et al., 2004; Braak et al., 2003; 
Goedert et al., 2012). 
1.3.2.1 The basal ganglia 
The basal ganglia are a selection of nuclei that play a key role in the control of body 
movements. The first coherent model of the basal ganglia circuitry was developed starting in 
the middle of the 80s (Albin et al., 1989; DeLong, 1990; Penney and Young, 1986), and 
described how the basal ganglia integrated information from different brain regions and 
generated feedback signals to the cerebral cortex. Today it is known that the basal ganglia 
have many functions beyond merely being an integrational relay structure. The term “basal 
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Figure 1.3 A simplified schematic drawing of the basal ganglia, including the nigrostriatal, corticostriatal, 
mesolimbic, mesocortical and mesoamygdaloid pathways. DA: dopamine; Glu: glutamate. Adapted from (Russo 
and Nestler, 2013). 
 
ganglia” refers to all gray matter structures located at the base of the cerebral hemispheres, 
but it is commonly used only to describe the interconnected nuclei substantia nigra pars 
reticulata (SNr) and SNc, striatum (caudate and putamen), globus pallidus pars externa (GPe) 
and GPi, and the STN (Obeso et al., 2008).  A simplified schematic drawing of the basal 
ganglia and their projection areas is presented in Figure 1.3. The striatum is the primary input 
nucleus of the basal ganglia. In humans and primates, the dorsal striatum consists of the 
caudate nucleus and putamen, separated by the internal capsule, whereas the ventral striatum 
consists of nucleus accumbens, the olfactory tubercle and islands of Calleja. In rodents the 
caudate nucleus and putamen are not visually separated, but the neuronal subpopulations are 
still organized into different functional compartments (Zeiss, 2005). The striatum consists of 
medium spiny neurons (MSN), representing nearly 95% of all striatal neurons (Kreitzer and 
Malenka, 2008), which either express stimulatory dopamine D1 receptors or inhibitory 
dopamine D2 receptors. A small proportion of MSN express both receptor types (Bertran-
Gonzalez et al., 2010). MSN provide inhibitory control by releasing γ-aminobutyric acid 
(GABA) onto the regions that they innervate. The striatum receives dopaminergic innervation 
from the SNc, and glutamatergic innervation from striatum and thalamus, which project onto 
the MSN. Dopamine release will activate dopaminergic receptors expressed on MSN, 
resulting in activation of the “direct” motor pathway (MSN expressing D1 receptors) 
projecting to GPi/SNr, or blockade of the “indirect” motor pathway (MSN expressing D2 
receptors) projecting to GPe, which in turn inhibits the STN. The STN in turn sends 
glutamatergic projections to GPi/SNr, the output region of the basal ganglia, which in turn 
send inhibitory GABAergic projections to thalamus. Activation of D1 receptors of the direct 
pathway leads to a net reduction of inhibition of the thalamus and initiation of movement. 
Activation of inhibitory D2 receptors of the indirect pathway leads to inhibition of thalamus 
and inhibition of movements. Under healthy conditions there is a very delicate balance 
between the activation of the direct and indirect basal ganglia pathways. PD is pathologically 
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characterized by a loss of dopaminergic neurons originating in the SNc projecting to the 
striatum, leading to an imbalance between the direct and indirect pathways and thus between 
the initiation and inhibition of movement, ultimately resulting in the cardinal motor 
symptoms of PD (Obeso et al., 2008; Wichmann and DeLong, 1998). PD is also 
characterized by a disinhibition of the glutamatergic STN, which is thought to contribute to 
the progressive neurodegeneration due to the excitotoxic properties of glutamate. The 
striatum also contains interneurons, the most prominent being the tonically active cholinergic 
interneurons which inhibit cortical glutamatergic output, and GABAergic fast-spiking 
interneurons which mediate intrastriatal feed-forward inhibition (Obeso and Lanciego, 2011). 
The basal ganglia also receive input from sub-cortical nuclei, including serotonergic 
innervation from the raphe nuclei, and noradrenergic innervation from locus coeruleus 
(McHaffie et al., 2005).  
Today it is established that the basal ganglia not only mediate the control of movement, but 
also motor learning, working memory and executive functions. It is also believed that the 
VTA plays a role in the non-motor symptoms of PD. Dopaminergic neurons of the VTA 
degenerate to between 36-55% in patients with PD (Uhl et al., 1985), meaning that they are 
relatively spared compared with dopaminergic neurons of the SNc. The VTA is a 
heterogeneous structure consisting of subpopulations of dopaminergic neurons with discrete 
projections and different electrophysiological properties (Roeper, 2013). For instance, the 
anterior and posterior VTA play different functional roles with regards to behavioural 
functions (Sanchez-Catalan et al., 2014). Apart from the well-studied dopaminergic 
neurons, the VTA also harbours GABAergic and glutamatergic neurons, as well as neurons 
that co-release dopamine and glutamate, which create different functional outputs (Walsh 
and Han, 2014). Recently a cluster of mainly GABAergic cells were identified, termed the 
tVTA, which form synapses with cells of the VTA and SNc and thus possibly can control 
the activity of dopaminergic neurons (Sanchez-Catalan et al., 2014). The projection from 
the VTA to the nucleus accumbens, a part of ventral striatum, compromises a well-
characterized reward circuitry of the brain, and is critical for the recognition of rewards and 
for the initiation of their consumption, thus playing a major role in addictive disorders (Koob 
and Le Moal, 2008). This circuitry is also involved in the recognition of aversive stimuli. The 
VTA also sends dopaminergic projections to basolateral amygdala, the CA1 region of the 
hippocampus and the prefrontal cortex (Russo and Nestler, 2013). These interconnected 
regions play key roles in reward, learning and memory functions, and receive serotonergic 
input from midbrain raphe nuclei and noradrenergic input from locus coeruleus (Russo and 
Nestler, 2013). These regions are also proposed to play roles in mood disorders (Drevets et 
al., 1992; Fu et al., 2004; Mayberg et al., 2000; McEwen, 1999; Sheline et al., 2001; Siegle et 
al., 2007).  
1.3.3 Non-dopaminergic neurotransmitter systems in PD 
PD does not exclusively affect the dopaminergic system, but is today considered a 
multisystem disorder. There is growing evidence that a non-dopaminergic pathological 
process underlies the non-motor symptoms of PD, and that this process may precede the 
degeneration of the dopaminergic system, as demonstrated in Table 1.2. The dopaminergic 
neurons projecting from the SNc to the striatum receive modulatory input from several 
neurotransmitter systems including the glutamatergic, cholinergic, serotonergic and 
noradrenergic systems, both at the cell bodies and at the terminals where these receptor types 
are expressed. Moreover, the GABAergic MSNs of the striatum express acetylcholine, 
glutamate, serotonin, adenosine, opiate and cannabinoid receptors on both cell bodies and 
terminals (Jenner, 2015). Nicotinic cholinergic receptors of the α4β2 and α6β2 subtypes are 
expressed on striatal cholinergic interneurons where they play a key role in regulating 
striatal activity, possibly playing a role in the paradoxical protective effect of tobacco 
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Figure 1.4 The modulation of corticostriatal glutamate release. A simplified schematic drawing of a 
corticostriatal synapse, indicating the potential roles of dopamine D2 receptors and retrograde endocannabinoid 
release in the inhibition of glutamate release. CB1R:  cannabinoid receptor type 1; DA: dopamine;  
eCB: endocannabinoids; Glu: glutamate; mGluR: metabotropic glutamate receptor. 
smoking in PD (discussed further in 1.3.5.2). Corticostriatal glutamate release is essential for 
voluntary movement, and may also exert neurotoxic effects when dysregulated, making it a 
promising target for therapeutic interventions in PD. Another glutamatergic region is the 
STN, which sends glutamatergic innervations to several regions of the basal ganglia, and in 
turn is innervated by GABAergic neurons. The work of this thesis has focused on the role of 
the glutamatergic system and trace-amine associated receptor 1 in PD, which are further 
elaborated upon below. 
1.3.3.1 The glutamatergic system in Parkinson’s disease 
Glutamatergic neurotransmission plays a crucial role in cognitive processes such as learning 
and memory, and alterations in glutamatergic neurotransmission has been implicated in non-
motor symptoms associated with PD, particularly cognitive dysfunctions (Gravius et al., 2010; 
Hsieh et al., 2012). Consistently, the antiglutamatergic drug memantine, an N-methyl D-
aspartate (NMDA) receptor antagonist, is used in the clinic to alleviate cognitive impairments 
and dementia in PD (Aarsland et al., 2009; Litvinenko et al., 2010). 
The general role of glutamate in the basal ganglia is to alter the excitability of neurons; to 
hyperpolarize or depolarize neurons (Conn et al., 2005). The striatum is the principal input 
structure of the basal ganglia, and receives excitatory glutamatergic input from neocortex and 
thalamus (McGeer et al., 1977; Smith and Villalba, 2008), as shown schematically in Figure 
1.3. The striatum also receives extensive dopaminergic innervation from SNc, making it a key 
region for integration of dopaminergic and glutamatergic input (Bouyer et al., 1984). 
Excitotoxic damage caused by excess glutamate has been proposed as a mechanism 
contributing to neurodegeneration (Rodriguez et al., 1998). The STN is glutamatergic and 
projects to the substantia nigra, including the SNc, where it is in a position to exert nigral 
excitotoxic cell damage (Rodriguez et al., 1998). Moreover, degeneration of nigrostriatal 
dopaminergic neurons leads to excess spontaneous glutamatergic corticostriatal activity, 
which has been demonstrated in the unilaterally 6-hydroxydopamine (6-OHDA) lesioned rat 
model using electrophysiology (e.g. (Gubellini et al., 2002)). Although the modulation of 
corticostriatal glutamatergic transmission by D2-like receptors has been demonstrated 
previously by electrophysiology in slice preparations (e.g. (Cepeda et al., 1993), the 
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underlying mechanism remains controversial. One interpretation is that activation of 
presynaptic D2 heteroreceptors at corticostriatal terminals suppresses synaptic transmission 
(Wang and Pickel, 2002). On the other hand, there is support for the role of the 
endocannabinoid (eCB) system in modulating glutamate release from cortical afferents 
projecting to striatum, possibly via D2 receptor induction (Mathur and Lovinger, 2012) 
(Figure 1.4). This mechanism has been explored further in study II.  
1.3.3.2 Trace amines and trace amine-associated receptor 1 
Endogenous trace amines, which are structurally related to monoamines and exist in low (0.1-
10 nM) concentrations throughout the mammalian brain, have in recent years emerged as 
potential modulators of dopaminergic functions (Branchek and Blackburn, 2003). Altered 
trace amine concentrations have been associated with neuropathological disorders related to 
the monoaminergic systems, including schizophrenia, depression and PD (Branchek and 
Blackburn, 2003). However, the functional role of trace amines remained elusive until 2001, 
when a family of receptors activated by trace amines, termed “trace amine-associated 
receptors”, were discovered (Bunzow et al., 2001; Borowsky et al., 2001). 
Trace amine-associated receptor 1 (TAAR1) has been identified as a modulator of many 
functions related to the monoaminergic systems, and increasing evidence suggest that 
TAAR1 can play a role in disorders related to monoaminergic systems, including PD. 
TAAR1 is expressed in monoaminergic systems of the brain, including the VTA and 
substantia nigra (Bunzow et al., 2001; Di Cara et al., 2011; Miller et al., 2005; Xie et al., 
2007). Previous in vitro experiments by Xie and Miller (Xie and Miller, 2009, 2008, 2007), 
using cell cultures and striatal synaptosomes, reported that TAAR1 agonism inhibited 
dopamine reuptake by the dopamine transporter (DAT), caused internalization of DAT, and 
reversed DAT function resulting in increased dopamine efflux, subsequently causing an 
increase in extracellular dopamine levels. There is convincing data that TAAR1 and D2 
receptors are highly co-expressed in dopaminergic neurons of the substantia nigra (Borowsky 
et al., 2001; Di Cara et al., 2011), where they may interact by forming heterodimers 
(Espinoza et al., 2011). This indicates that TAAR1 can modulate dopaminergic functions by 
interacting with several components of dopaminergic signaling. 
Agonists at TAAR1 have been proposed as potential means to treat neuropsychiatric 
disorders characterized by enhanced dopaminergic neurotransmission (Revel et al., 2013, 
2011). TAAR1 is activated by a wide range of endogenous ligands, including trace amines, 
biogenic amines including dopamine and dopamine analogs, 3-methylated metabolites of 
catecholamines, and by synthetic substances including amphetamine derivatives and ergolines 
(Bunzow et al., 2001). None of these compounds are selective to TAAR1, which hampered 
the design and interpretation of mechanistic studies before the development of the first 
specific TAAR1 antagonist EPPTB (Bradaia et al., 2009) and agonist RO5166017 (Revel et 
al., 2011). Previous experiments in wild-type (WT) animals showed no behavioural effects 
following oral administration of RO5166017 except for a minor decrease in locomotor 
activity (Revel et al., 2011). A high dose of RO5166017 also elicited a mild anxiolytic effect 
in the stress-induced hyperthermia paradigm, and prevented cocaine-induced hyperactivity 
and stereotypies (Revel et al., 2011). None of these effects were present in TAAR1 knock-out 
(KO) mice, suggesting mediation via TAAR1. RO5166017 administered intraperitoneally 
(i.p.) reduced locomotor activity in mice lacking DAT, a rodent model characterized by 
spontaneous hyperactivity, but failed to do so in mice that lacked both DAT and TAAR1 
(Revel et al., 2011), suggesting that this effect was mediated by TAAR1 independently of 
DAT. RO5166017 also blocked hyperlocomotion induced by an NMDA-receptor antagonist, 
an effect abolished in TAAR1 KO animals, suggesting that TAAR1 activation may mediate 
an antipsychotic effect (Revel et al., 2011). Also, the full TAAR1 agonist RO5256390 and the 
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partial agonist RO5263397 were found to mediate antipsychotic-like, pro-cognitive and anti-
depressant effects in rodents and primates (Revel et al, 2013), further supporting TAAR1 as a 
potential target for treatment of negative and cognitive symptoms of schizophrenia. 
Another factor that has hampered studies of the functions of TAAR1 is that the TAAR1 
antagonist EPPTB does not readily cross the blood-brain barrier. Although TAAR1 KO 
animals have been developed, it is possible that a congenital deletion of TAAR1 leads to 
developmental adaptations, which would otherwise be circumvented by the use of a selective 
antagonist. Previous experiments in mice, where the TAAR1 gene was targeted, showed that 
TAAR1 KO mice did not display any genotype-related differences regarding their general 
state of health, motor functions, overall activity or anxiety-like behaviour compared to control 
animals, apart from a deficit in the prepulse inhibition test (Lindemann et al., 2008; Wolinsky 
et al., 2007), suggesting a schizophrenia-like phenotype. Moreover, TAAR1 KO animals 
expressed a 262% higher level of high-affinity D2 receptors in the striatum compared with 
WT mice (Wolinsky et al., 2007), as well as a higher sensitivity towards amphetamine. The 
latter was manifested as enhanced amphetamine-induced extracellular dopamine and 
noradrenaline concentrations in the striatum as measured by microdialysis, and higher 
locomotor activity in the open field test compared with control animals (Achat-Mendes et al., 
2012; Lindemann et al., 2008; Wolinsky et al., 2007). Slice experiments in the VTA of 
TAAR1 KO mice revealed enhanced spontaneous firing of dopaminergic neurons in KO 
compared with WT animals, suggesting that TAAR1 mediates a dampening effect on the 
activity of dopaminergic neurons upon activation (Lindemann et al., 2008), which is 
supported by slice experiments using specific ligands (Bradaia et al., 2009; Revel et al., 2011). 
However, the enhanced dopamine neuron firing rate observed in TAAR1 KO animals did not 
enhance basal levels of extracellular dopamine as detectable by microdialysis (Lindemann et 
al., 2008). It is highly likely that the enhanced potency of antipsychotic drugs in TAAR1 KO 
animals is related to the elevated proportion of high-affinity D2 receptors in this model 
(Wolinsky et al., 2007), which in turn may be a developmental adaptation induced by a 
congenital absence of TAAR1. Paradoxically, mice overexpressing TAAR1 did not display 
any basal behavioural phenotype, but displayed elevated concentrations of dopamine and 
noradrenaline in nucleus accumbens, and an increased firing rate of dopaminergic neurons in 
the VTA (Revel et al., 2012). These mice were also less sensitive to amphetamine.  
Changes in dopamine release and dopamine receptor binding is implicated in the 
behavioural sensitization of psychostimulants (Steketee and Kalivas, 2011). Amphetamine, 
metamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) are agonists of 
TAAR1, suggesting that TAAR1 may mediate the reinforcing effects of these compounds 
(Achat-Mendes et al., 2012; Bunzow et al., 2001; Di Cara et al., 2011). Indeed, previous work 
demonstrated that TAAR1 KO mice exhibit more psychomotor effects compared with WT 
mice in response to amphetamine and metamphetamine respectively, and increased striatal 
release of biogenic amines compared with WT mice in response to amphetamine (Achat-
Mendes et al., 2012; Lindemann et al., 2008; Wolinsky et al., 2007). In vitro experiments 
revealed that metamphetamine enhances dopamine efflux from cells via a TAAR1-dependent 
mechanism (Xie and Miller, 2009). Moreover, a partial and a full TAAR1 agonist each 
suppressed cocaine-seeking after withdrawal from chronic cocaine self-administration, 
suggesting TAAR1 as a potential target for the treatment of cocaine addiction (Pei et al., 
2014).  
These data from previous studies highlight a multifaceted role of TAAR1 in a range of 
functions related to the dopaminergic system. In study II, we have on further delineating the 
role of TAAR1 in experimental PD. 
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1.3.4 Pathogenesis of Parkinson’s disease 
Several mechanisms contributing to cell death have been proposed in PD. However, the 
reason for the vulnerability of some cell types and resistance of other cell types in PD is not 
adequately understood. The mechanisms most relevant to this thesis are described below. 
1.3.4.1 Mitochondrial dysfunction and oxidative stress 
Defective mitochondrial function, accompanied by increased oxidative stress, has been 
shown to play an important role in the pathogenesis of PD (Schapira, 2008). The normal 
function of mitochondria involves the production of energy in the form of ATP via the 
mitochondrial respiratory chain, as well as the regulation of cell death, calcium metabolism 
and the production of ROS. The mitochondrial respiratory chain, also called the electron 
transport chain, consists of enzymatic complexes I-IV, which are embedded in the inner 
mitochondrial membrane. Complexes I-IV catalyse redox reactions where electrons are 
transferred from a donor, produced by the Krebs cycle in the matrix of the mitochondrion, 
to an acceptor molecule (Mitchell, 2011). These redox reactions create an electrochemical 
gradient through the inner mitochondrial membrane which drives the synthesis of ATP 
(Mitchell, 2011). Mitochondria are also a main source of ROS and reactive nitrogen species 
(RNS), produced by their multiple electron carriers, but they also normally harbour 
extensive antioxidant defence mechanisms to prevent harmful oxidative stress (Lin and 
Beal, 2006). Mitochondria damage, induced by ROS for instance, may result in an 
imbalance between ROS generation and removal, and subsequently to enhanced ROS levels 
(Andreyev et al., 2005). This in turn would increase the amount of cell damage and 
misfolded proteins, thus increasing the demand for protein removal by the ubiquitin-
proteasome system. Complex I deficiency has been described in postmortem brain samples 
from patients suffering from PD (Schapira et al., 1989). It should be noted that many of the 
genes associated with PD have been shown to affect mitochondrial functions. 
The brain is the most metabolically active organ of the body, and thus its internal iron 
concentration is very high (Hare et al., 2015). Superoxide and H2O2 are intermediates of 
oxygen reduction and potent oxidants in the presence of iron. When reacting with ferrous 
iron, Fe
2+
, they will form hydroxyl radicals, which can cause cytotoxicity by lipid 
peroxidation. The production of hydroxyl radicals is normally handled by specific 
antioxidant defense mechanisms. Neurons of the SNc contain neuromelanin, a byproduct of 
dopamine synthesis which facilitates iron accumulation (Sulzer et al., 2000). Although 
neuromelanin has been proposed to increase cellular vulnerability of PD, it should be noted 
that the more resistant VTA neurons contain similar amounts of neuromelanin as neurons of 
the SNc (Dias et al., 2013). Iron-mediated oxidative stress is prevented by sequestration of 
free iron by the cytosolic protein ferritin, which can store up to 4500 excess iron atoms that 
are released when required to prevent free iron from reaching high concentrations (Rouault, 
2013). Ferritin also catalyzes the oxidation of ferrous iron (Fe
2+
) to the more stable form 
ferric iron (Fe
3+
) upon storage. Ageing is associated with enhanced accumulation of iron, 
which happens specifically in naturally iron-rich regions, including the basal ganglia and 
cortex, probably by mechanisms including increased ferritin levels and increased activity of 
haem oxygenase-1, which releases free iron by degrading haem. Several studies have 
reported that mechanisms facilitating iron transport from the SNc are deficient in PD (Jin et 
al., 2011; Lei et al., 2012). Consistently, iron accumulation is higher in the neurons of the 
SNc compared with other cell types. Early-life iron exposure has been proposed to be a 
contributing factor to PD in later life, although the impact of dietary iron on the risk of 
developing PD remains controversial (Hare et al., 2015). 
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Mitochondria are believed to contribute to ageing via the accumulation of mitochondrial 
DNA mutations (Corral-Debrinski et al., 1992) and the production of ROS. Ageing is a 
prominent risk factor not only for PD, but also for other neurodegenerative disorders 
including Alzheimer's disease and ALS. Indeed, oxidative damaged has been implicated in 
age-induced cognitive decline in humans (Lu et al., 2004). Moreover, enhancement of the 
natural antioxidant defence of mitochondria has been reported to promote longevity in 
drosophila (Ruan et al., 2002; Sun et al., 2002) and mice (Schriner, 2005).  
Since mitochondrial dysfunction has been strongly implicated in the pathogenesis of PD, 
drugs that improve mitochondrial functions may be neuroprotective in PD. However, 
clinical studies using vitamin E with coenzyme Q10, an electron carrier for mitochondrial 
complexes I and II of the electron transport chain and a scavenger of free radicals, and 
creatinine, were terminated prematurely due to lack of effect in early PD (Kalia et al., 
2015). One complication of using ROS scavengers in the treatment of neurodegenerative 
disorders is that they impair autophagy, which in itself may be useful in the treatment of 
neurodegenerative disorders (Metcalf et al., 2012), as discussed below. 
1.3.4.2 Dysfunctional protein folding and degradation 
Many proteins must fold into a specific three-dimensional structure in order to gain 
functional activity, and misfolding may generate protein aggregation or the generation of 
toxic species (Hartl et al., 2011). α-synuclein aggregation has been associated with 
dysfunctional proteostasis, i.e. of the cellular machineries that normally handle protein 
folding and the degradation of dysfunctional proteins. This includes the chaperone systems 
that regulate protein folding and the refolding of misfolded proteins (Hartl et al., 2011), the 
ubiquitin-proteasomal pathway as well as the autophagy-lysosomal pathway, which are 
responsible for the elimination of  toxic proteins (Tyedmers et al., 2010).  
Protein degradation via the ubiquitin-proteasomal pathway is the most common 
mechanism to degrade proteins in the mammalian cytosol and nucleus (Ciechanover et al., 
1980; Hershko et al., 1983, 1982). This mechanism requires two steps. During the first step, 
termed “conjugation”, multiple ubiquitin molecules are covalently attached to the protein 
destined for degradation. During the second step, termed “degradation”, the ubiquitin-
tagged protein is degraded by the 26S proteasome. Ubiquitin is often a constituent of Lewy 
bodies, which has led to the common hypothesis that dysfunctions of the ubiquitin-
proteasomal pathway may contribute to PD. It should be noted that ubiquitin is also 
associated with other functions besides proteasomal targeting, including the autophagic-
lysosomal system (Matsuda and Tanaka, 2010). 
The autophagic-lysosomal pathway plays an important function in neurons by removing 
aggregation-prone proteins. Autophagy is the catabolic mechanism by which cells degrade 
dysfunctional and redundant cellular components via lysosomes. This process allows 
recycling of larger cellular components, removal of toxic aggregates, and promotes cellular 
survival by maintaining energy levels during starving (Metcalf et al., 2012). There are three 
described forms of autophagy: macroautophagy; microautophagy and chaperone-mediated 
autophagy. Macroautophagy is the main autophagy pathway and used to remove damaged 
organelles and redundant proteins. Cytoplasmic components targeted for degradation are 
isolated within double-membraned vesicles called autophagosomes, which then mature by 
fusing with endosomes and lysosomes to induce degradation via acidic lysosomal 
hydrolases and recycling of the contents of the autolysosome (Eskelinen, 2008). During 
microautophagy, cytoplasmic contents are taken up directly by the lysosome via inward 
folding of the lysosomal membrane (Mijaljica et al., 2011). Chaperone-mediated autophagy 
is a complex mechanism that specifically targets cytosolic proteins marked with a 
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recognition site for an hsc70-containing complex. This pathway allows proteins to bind a 
chaperone, after which they are translocated via the lysosome membrane for degradation. 
Autophagy normally plays a part in programmed cell death, in the degradation of infectious 
particles, and in cellular repair mechanisms. Failure of autophagy to degrade damaged 
proteins and organelles has been implicated in the accumulation of cell damage, aging and 
neurodegenerative disorders, including both PD and Alzheimer’s disease (Cuervo et al., 
2005; Menzies et al., 2015; Rajawat et al., 2009).  
There are indications of relationships between abnormal protein accumulation and 
degradation, oxidative stress, and mitochondrial dysfunction. For instance, α-synuclein 
overexpression in mice treated with the neurotoxin MPTP has been shown to impair 
mitochondrial function, enhance oxidative stress and aggravate MPTP-induced nigral 
neurodegeneration, indicating an interaction between α-synuclein and MPTP in vivo (Song 
et al., 2004). It has been proposed that α-synuclein may interact with mitochondria by 
interacting with their outer membranes, by being transported into mitochondria via protein 
transportation mechanisms, or by impairing the transcription of nuclear encoded genes 
required for mitochondrial function (Beal, 2004). Moreover, rotenone, a complex I inhibitor 
used to induce experimental Parkinsonism in rodents, increases the generation of α-
synuclein aggregates, an effect which was abolished following the recovery of 
mitochondrial metabolism (Lee et al., 2002). The clearance of damaged mitochondria via 
autophagy is partly mediated by PARKIN and PINK1, two genes implicated in PD (Durcan 
and Fon, 2015). 
1.3.4.3 Neuroinflammation 
Chronic inflammation is a major characteristic of PD, and patients display increased levels of 
pro-inflammatory molecules including TNF-α, iNOS and IL-1β both in cerebrospinal fluid 
and postmortem brain (Dobbs et al., 1999; Mogi et al., 1994; Reale et al., 2009). Today, there 
is increasing evidence that the immune system, especially glial cells, plays a role in PD also 
during early disease stages, indicating that this inflammatory response may not be triggered 
by the neurodegenerative process (Herrero et al., 2015). It is known that microglial cells, 
which play an important neuroprotective role by maintaining the neuronal environment and 
scavenging the CNS for pathogens, are activated during the neurodegenerative process in PD 
(Sanchez-Guajardo et al., 2015). Microglial changes, termed “microgliosis”, have commonly 
been described in patients with PD and in animal models, and appear in regions characterized 
by α-synuclein pathology. In animal models of PD recapitulating α-synuclein pathology, 
microgliosis appeared before neuronal death (Sanchez-Guajardo et al., 2015).  
Genome-wide analysis studies have revealed a number of susceptibility loci related both to 
innate and adaptive immune functions associated with an increased risk of developing PD 
(Herrero et al., 2015). Moreover, several genes associated with familial and sporadic PD, 
including LRRK2, SNCA, PARK2, PARK7 and PLA2G6 are expressed in microglia and 
astrocytes, which suggests a role of these genes in neuroinflammation (Russo et al., 2014). 
Interestingly, prolonged use of non-steroidal anti-inflammatory drugs, and of ibuprofen in 
particular, may reduce the risk of developing PD (Rees et al., 2011). Ageing is also known to 
affect the immune system per se, and advancing age has been specifically associated with 
chronic mild inflammation of the SNc, which may render these dopaminergic neurons more 
vulnerable to neurodegeneration in PD (Kanaan et al., 2010).   
1.3.4.4 Excitotoxic cell damage 
The excitatory neurotransmitter glutamate plays an important role in the normal basal 
ganglia circuitry, and neurodegeneration of dopaminergic nigral neurons results in altered 
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dynamics throughout the basal ganglia, as explained further in 1.3.3.1. This imbalance may 
accelerate neuronal degeneration due to excitotoxic processes (Blandini et al., 2000). This 
also means that glutamate release may provide a target for neuroprotective treatments. 
However, due to rapid release and reuptake mechanisms, glutamatergic neurotransmission 
has been technically difficult to measure in vivo using conventional methods. Thus, 
previous in vivo microdialysis studies of striatal tonic glutamate concentrations following 
neurotoxin-induced dopamine denervation have been inconsistent; reporting enhanced 
(Meshul et al., 1999), unaltered (Corsi et al., 2003; Robelet et al., 2004), or decreased (Reid 
et al., 1990) glutamate concentrations following lesioning. These inconsistent results may 
be related to methodological differences, including sampling rate and size of the probe, 
species used, anesthetic agent used, and time span elapsed between lesion and recording, 
the latter which may affect the level of compensatory regeneration of multiple 
neurotransmitter systems. Therefore, in study II we used an enzyme-based microelectrode 
array that allowed detection of low glutamate levels on a subsecond time scale, in order to 
monitor the fast temporal fluctuations of glutamatergic neurotransmission in anaesthetized 
PD models (Hascup et al., 2008). 
1.3.5 Aetiology of Parkinson’s disease  
The cause of sporadic PD is unknown, but is generally believed to be caused by a 
combination of factors, including environmental exposures and gene-environment 
interactions.  
1.3.5.1  Genetic factors 
Genetic factors have been linked to around 10% of all PD cases, which are commonly cases 
of early-onset PD. Mutations in up to 18 chromosomal regions, termed PARK1-18, have 
been associated with PD (Klein and Westenberger, 2012). Six of these genes are known to 
cause monogenic, familial PD: SNCA (PARK1 and 4), LRRK2 (PARK8), Parkin (PARK2), 
DJ-1(PARK7), PINK1 (PARK6) and ATP13A2 (PARK9) (Klein and Westenberger, 2012). 
SNCA encodes α-synuclein, a constituent of Lewy bodies both in familial and sporadic PD 
(Dehay et al., 2015). Three missense mutations (A53T, A30P and E46K), duplications and 
triplications of the SNCA gene are known to cause PD (Bekris et al., 2010). LRRK2 is a 
tyrosine kinase-like protein, which has been suggested to be involved in neuroinflammation 
(Russo et al., 2014). It is present in the cytoplasm and the mitochondrial outer membrane (Ito 
et al., 2007). PARK2 encodes the protein Parkin, which is localized in the cytosol and Golgi 
apparatus (Shimura et al., 1999). Parkin can also localize to mitochondria, where it has been 
proposed to modulate the transcription and replication of mitochondrial DNA in proliferating 
cells (Kuroda et al., 2006), to protect mitochondrial DNA from oxidative damage (Rothfuss 
et al., 2009), to modulate the activity of mitochondrial complex 1 and the production rate of 
ROS (Kuroda et al., 2006), and to play a role in targeting proteins for proteasomal 
degradation (Lonskaya et al., 2013). PARK7 encodes the protein DJ-1, a cytoplasmic protein 
that can translocate to the mitochondria (Zhang et al., 2005). It has been proposed to harbour 
antioxidant properties (Abou-Sleiman et al., 2003; Canet-Avilés et al., 2004), to scavenge 
ROS via auto-oxidation (Taira et al., 2004), and to prevent aggregation of α-synuclein 
(Batelli et al., 2008). PINK1 encodes a mitochondrial protein of unknown function expressed 
both in the brain and in systemic organs, which is proposed to protect from stress-induced 
mitochondrial dysfunction (Silvestri et al., 2005). ATP13A2 is a lysosomal membrane protein 
with an ATPase domain, and its function is currently unknown (Ramirez et al., 2006). 
Common variation in 3 genes, LRRK2, SNCA and microtubule-associated protein tau 
(MAPT), and loss-of-function mutations in the glucocerebrosidase gene (GBA) have also 
been shown to be susceptibility factors for PD (Bonifati, 2014).  
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Table 1.3. Genes associated with monogenic PD 
 
1.3.5.2 Environmental factors 
Several lifestyle factors have been associated with a decreased risk for developing PD, 
including smoking and coffee consumption (Derkinderen et al., 2014). A meta-analysis 
demonstrated strikingly that PD was 60% lower among cigarette smokers compared with 
never smokers, and 30% lower in coffee drinkers compared with non-coffee drinkers.  
The mechanism underlying the protective effect of smoking is not known, but one 
proposed mechanism is that tobacco smoke can inhibit the uptake of neurotoxins by 
inhibiting MAO-B and/or by binding to nicotinic receptors, thus competitively inhibiting 
potential neurotoxins (Morens et al., 1995). Nicotinic cholinergic receptors of the α4β2 and 
α6β2 subtypes are expressed on striatal cholinergic interneurons, where they play a key role 
in regulating striatal activity and dopamine release (Quik et al., 2009). Nicotinic 
acetylcholine receptors have been shown to exert neuroprotective and antidyskinetic effects 
in experimental animal models of PD, and, in particular, α7 nicotinic acetylcholine 
receptors have been proposed as therapeutic targets in the management of PD (Quik et al., 
2015). However, a study in 8 patients with early-onset Parkinsonism on the effects on 
nicotine chewing gum showed improved symptoms after taking nicotine chewing gum, but 
only in patients who were smokers (Mitsuoka et al., 2002). A short-term trial on the effects of 
nicotine chewing gum in 46 patients with PD showed no effects on PD symptoms (Clemens 
et al., 1995) 
As for coffee, this protective effect may be mediated via caffeine, since caffeine from 
non-coffee sources, but not decaffeinated coffee, has also been shown to be inversely 
associated with the risk of developing PD (Ascherio et al., 2001). Caffeine has been shown 
to down-regulate neuroinflammatory responses and nitric oxide production (Yadav et al., 
2012), thus potentially preventing cell death. It has also been shown that in the human 
Gene (also known as) Official full name Function of protein in PD 
SNCA 
(PD1; NACP; PARK1; PARK4) 
Synuclein, alpha (non A4 
component of amyloid precursor) 
Constituent of Lewy bodies 
LRRK2 
(PARK8; RIPK7; ROCO2; 
AURA17; DARDARIN) 
Leucine-rich repeat kinase 2 Associated with mitochondria 
Neuroinflammation? 
PARK2 
(PRKN; PDJ; AR-JP; LPRS2) 
Parkin RBR E3 ubiquitin protein 
ligase 
Modulates mitochondrial functions 
Proteasomal degradation 
PARK7 
(DJ-1; HEL-S-67p) 
Parkinson protein 7 Antioxidant 
ROS scavenger 
PINK1 
(BRPK; PARK6) 
PTEN induced putative kinase 1 Unknown 
Associated with mitochondria 
ATP13A2 
(CLN12; KRPPD; PARK9; 
HSA9947) 
ATPase type 13A2 Unknown 
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brain, at doses normally consumed, caffeine increases the levels of dopamine D2 and D3 
receptors in the striatum, which may account for the stimulating effect of caffeine (Volkow 
et al., 2015). Caffeine is an adenosine receptor antagonist which binds to all types of 
adenosine receptors (Ribeiro and Sebastio, 2010).  Adenosine receptors of the A2A subtype 
have been shown to reduce the postsynaptic effects of dopamine depletion, resulting in 
alleviation of the motor symptoms of PD (Schwarzschild et al., 2006). In the striatum, A2A 
receptors colocalize with D2 receptors and form A2A-D2 receptor heteromers, whereby they 
elicit opposite actions on neuronal adenylate cyclase and cAMP production (Ferré et al., 
2007). Thus, A2A receptors inhibit D2 receptor signalling upon activation, whereas A2A 
blockade enhances D2 receptor signalling (Pollack and Fink, 1995). A2A receptor blockade 
has been shown in both preclinical and clinical studies to enhance the effect of L-DOPA 
treatment and to alleviate L-DOPA-induced dyskinesias (Dungo and Deeks, 2013). The 
selective A2A receptor antagonist istradefylline was recently approved for adjunctive 
treatment of PD in Japan (Dungo and Deeks, 2013), specifically used to reduce “off” time 
during L-DOPA treatment (LeWitt et al., 2008).  In view of the recent hypothesis that PD 
starts in the gut (discussed in section 1.3.6), it is also interesting to note that both coffee 
consumption (Jaquet et al., 2009; Nakayama and Oishi, 2013) and smoking cessation 
(Biedermann et al., 2013) have been shown to affect the human intestinal microbiota.  
Occupational risk factors, including welding and exposure to heavy metals including 
aluminium, amalgam, copper, iron, lead, manganese or zinc have been proposed to increase 
the risk of PD, but no conclusive evidence has been found (Lai et al., 2002). Increased iron 
levels have been found in the substantia nigra of PD patients, where it may contribute to 
increased formation of free radicals. As mentioned in 1.3.4.1, the effects of dietary iron on 
the risk of developing PD remains inconclusive. Another occupational risk factor is 
exposure to pesticides, which will be discussed in part 1.4 since several successful animal 
models are based on this association. 
Type 2 diabetes mellitus, a metabolic disorder associated with several psychiatric and 
neurodegenerative disorders (Kalaria, 2009; Llorente and Urrutia, 2006), has also been 
shown to be associated with an increased risk of developing PD, independently of coffee 
consumption, smoking or body weight (Hu et al., 2007). Diabetes may also be a risk factor 
for drug-induced Parkinsonism (Ma et al., 2009). Moreover, PD patients suffering from 
diabetes mellitus suffer from more severe cognitive impairments compared with non-
diabetic PD patients (Bohnen et al., 2014). Chronic inflammation, impaired mitochondrial 
function and oxidative stress have also been proposed in the pathogenesis of type 2 
diabetes, and a shared pathophysiology with PD has been proposed since the 1960s, but 
remains controversial (Lima et al., 2014). The role of insulin in the CNS is not yet well 
understood. However, insulin receptors are expressed throughout the CNS, including the 
VTA, SNr, hippocampus, amygdala and olfactory regions (Unger et al., 1991a, 1991b), 
where they appear to modulate a vast array of functions ranging from feeding behaviour 
and energy storage to cognitive functions (Bloemer et al., 2014; Filippi et al., 2013; 
Sandoval et al., 2009). Patients with PD have reduced levels of insulin receptors in the 
basal ganglia, which correlates with the loss of tyrosine hydroxylase (TH) mRNA (Moroo 
et al., 1994). Moreover, dopamine depletion has been shown to influence insulin levels and 
increase insulin resistance in experimental models of PD (Morris et al., 2011, 2008). 
Dopaminergic drugs, including L-DOPA and dopamine agonists, also influence insulin 
production, insulin resistance and glycaemic control (Sirtori et al., 1972). Interestingly, 
recent preclinical and clinical studies have shown that drugs developed for the treatment of 
diabetes, including analogues of incretin peptides and a GLP-1 receptor agonist, may have 
neuroprotective effects both in PD and in Alzheimer’s disease (Hölscher, 2014; 2012).  
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1.3.6 Parkinson’s disease and the gut  
Gastrointestinal dysfunction has, during the past 30 years, been recognized as a frequent 
and debilitating non-motor symptom of PD (Pfeiffer, 2011; 2003). Notably, gastrointestinal 
complications may arise 12-20 years before the onset of motor symptoms in patients 
subsequently diagnosed with PD, suggesting that these symptoms may appear before any 
nigral pathology (Abbott et al., 2001; Savica et al., 2009). Consistently, PD is associated 
with Lewy body accumulation in the enteric nervous system (Kupsky et al., 1987; 
Wakabayashi et al., 1989). Moreover, loss of dopaminergic neurons in the enteric nervous 
system has been reported in PD patients with severe constipation (Singaram et al., 1995). 
Gastrointestinal dysfunction has also been recapitulated by experimental models of PD, 
including 6-OHDA-, MPTP- and rotenone-treated rodents (Anderson et al., 2007; Greene et 
al., 2009; Natale et al., 2010; Tian et al., 2008). In recent years, a role of colonic 
inflammation has been proposed in PD (Clairembault et al., 2014; Devos et al., 2013).  
Indeed, based on the postmortem topographic distribution of Lewy bodies in PD patients, 
Braak and colleagues proposed that PD may originate outside the CNS, possibly via the 
exposure to an unidentified environmental pathogen entering postganglionic neurons via 
the intestinal lining of the gastrointestinal tract, subsequently spreading via the vagal nerve 
to the CNS (Braak et al., 2006; Braak et al., 2003). This hypothesis is supported by a study 
reporting that full truncal vagotomy is associated with a decreased risk of developing PD 
later in life, both compared with the general population and with patients that underwent 
super-selective vagotomy (Svensson et al., 2015). A recent study also reported that α-
synuclein from the brain lysate of a PD patient injected into the wall of the gastrointestinal 
tract of Sprague Dawley rats was taken up and transported retrogradely via the vagal nerve 
to the brain (Holmqvist et al., 2014). These observations shed new light on the hypothetic 
aetiologies of PD. 
1.3.7 Gender differences in Parkinson’s disease 
PD has been estimated to affect up to 3% of the population in the industrialized world, 
affecting 1% of people over the age of 60 (Nussbaum and Ellis, 2003). Several reports 
found a higher prevalence of PD in men compared with women (de Lau and Breteler, 
2006), which may be linked to the potential neuroprotective properties of oestrogen 
demonstrated both in vitro and in vivo (Saunders-Pullman, 2003). Premenopausal women 
have been reported to display a worsening of symptoms and a need for more L-DOPA 
during menstruation, when oestrogen levels are reduced (Quinn and Marsden, 1986; Tolson 
et al., 2002). Moreover, oestrogen replacement in postmenopausal women has been shown 
to improve cognitive functions (Jacobs et al., 1998; Shaywitz et al., 1999; Sherwin, 1988; 
Verghese et al., 2000), the latter which may delay the development of cognitive 
impairments and dementia in PD (Marder et al., 1998). The clinical features of PD also 
appear to differ between female and male patients. Women have been reported to develop 
more dyskinesias at equivalent doses of L-DOPA, to require lower doses of L-DOPA 
compared with men (even when doses are adjusted for body weight), and to have a milder 
motoric symptomatology after 5 years of disease progression compared with male patients 
(Lyons et al., 1998; Penney et al., 1996). Gender differences in the manifestation of non-
motor functions have also been reported in drug-naïve PD patients, with male patients 
performing significantly worse on odour identification tests and cognitive tests compared 
with female patients, and female patients presenting with higher anxiety rates and poorer 
visuospatial abilities compared with male patients (Liu et al., 2015). Interestingly, genetic 
factors may also have a different impact in women and men. A recent study of the link 
between the genes LMX1A and LMX1B, which were the focus of study III, and PD, 
revealed that four single nucleotide polymorphisms (SNPs) in LMX1A and two SNPs in 
LMX1B were associated with PD in women but not in men, whereas, conversely, two SNPs 
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in LMX1A and two SNPs in LMXB were associated with PD in men but not in women 
(Bergman et al., 2009). This indicates that PD-associated genes may interact with oestrogen 
or other sex-specific transcription factors, thus affecting the subsequent risk of developing 
PD (Bergman et al., 2009). Apart from hormonal differences between women and men, it is 
possible that occupational and life-style factors, which, for instance, may affect the 
exposure to environmental toxins, also account for gender differences in PD. Interestingly, 
gender differences may also differ with ethnicity since the higher incidence rates of PD in 
men are reported exclusively in studies conducted in Western populations, but not in Asian 
populations (Alves et al., 2008).  
1.4 EXPERIMENTAL MODELS OF PARKINSON’S DISEASE 
Valid animal models that mimic the progressive disease state of PD are essential tools to 
better understand the early pathogenesis of PD. The two toxin-based animal models 
predominantly used in preclinical PD research, the 6-OHDA-induced model and the MPTP-
induced model, induce an acute ablation of the dopaminergic system and thus do not 
successfully model the progressive nature of PD. Very few studies have been performed to 
address the early pathophysiology of PD, partially due to the absence of valid progressive 
animal models. In the studies presented in this thesis, we have evaluated novel models of 
progressive PD and used them to learn more about the early pathological changes in PD-like 
states. In addition, we have used 6-OHDA lesioned mice as a well characterized comparison 
to the novel models investigated. We also used 6-OHDA lesioned mice to study L-DOPA-
induced side effects, since this model is particularly useful to this end. Below is a brief 
overview of current experimental models of PD. 
1.4.1 Toxin-induced models of Parkinson’s disease 
Neurotoxin-induced models represent the oldest experimental PD models. The common 
feature of all neurotoxin-induced models is their ability to induce oxidative stress, thus 
damaging dopaminergic neurons in a way that mimics the pathology of human PD.  
1.4.1.1 The 6-hydroxydopamine lesioned model 
The first toxin-induced animal model of PD to be generated was the 6-OHDA model 
(Ungerstedt et al., 1974). In this well-established model, dopaminergic neurons projecting 
from the SNc to the striatum are unilaterally ablated by the neurotoxin 6-OHDA. 6-OHDA 
is a hydroxylated analogue of dopamine with a high affinity for DAT, which does not cross 
the blood-brain barrier and thus must be locally injected into the brain. Upon DAT-
mediated transportation of 6-OHDA into the neuron, 6-OHDA accumulates in mitochondria 
where it inhibits complex I (Blandini and Armentero, 2012). 6-OHDA can also auto-
oxidate, resulting in the production of hydrogen peroxide (H2O2) (Blandini and Armentero, 
2012). 6-OHDA is commonly injected directly into the SNc or into the medial forebrain 
bundle (MFB), the latter harbouring projections of the A9 dopaminergic cell group, which 
originates in the SNc and terminates in the striatum. Dopaminergic neurons start to 
degenerate 12 hours after the 6-OHDA injection, and after 2-3 days there is a marked loss 
of dopaminergic terminals in the striatum accompanied by dopamine depletion, 
subsequently leading to a 90-100% loss of dopaminergic neurons (Blandini and Armentero, 
2012). It is common to perform SNc/MFB 6-OHDA lesions unilaterally, leaving one 
hemisphere intact, which increases the viability of the animals and provides a useful model 
system to study and quantify L-DOPA-induced dyskinesias and stereotypies (Lundblad et 
al., 2004; Ungerstedt and Arbuthnott, 1970). Unilaterally lesioned animals display a 
characteristic rotational behaviour when challenged with drugs that stimulate striatal 
dopamine receptors directly or indirectly, such as apomorphine, L-DOPA and amphetamine 
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(Ungerstedt and Arbuthnott, 1970; Ungerstedt, 1971; Von Voigtlander and Moore, 1973). In 
another 6-OHDA-induced model the injections are made into the striatum, often bilaterally, 
resulting in a comparatively milder and progressive loss of dopaminergic neurons over 4-6 
weeks post-injection (Sauer and Oertel, 1994).  
1.4.1.2 The MPTP model 
It is known that humans exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
present with a syndrome that involves many key features of PD, including neurological 
symptoms and a selective neurodegeneration of dopaminergic neurons. The selective 
nigrostriatal toxicity of MPTP was first described in 1982, following the occurrence of 
chronic Parkinsonism in four young drug users from Northern California after injecting a 
preparation of synthetic heroin contaminated with MPTP (Langston et al., 1983). MPTP is 
transformed into its active metabolite 1-methyl-4-phenylpyridinium ion (MPP+) by MAO-B 
upon crossing the blood-brain barrier, and is then transported into dopaminergic neurons by 
DAT where it blocks mitochondrial complex I activity (Blandini and Armentero, 2012). 
Systemic injections of MPTP induce L-DOPA responsive Parkinsonism that recapitulate the 
cardinal symptoms of PD, and has thus proved useful for modelling PD in mice and primates. 
Rats, however, are resistant to systemic MPTP injections via a mechanism currently not 
understood. The MPTP-model has highlighted both the involvement of mitochondria in PD-
associated neurodegeneration, and the role of pesticides and environmental toxins in the 
aetiology of PD (see below), since there are structural similarities between MPTP, MPP+ and 
pesticides, including paraquat. One limitation of the MPTP-induced model is that the nigral 
lesions are not accompanied by the formation of Lewy bodies (Forno et al., 1996), one key 
pathological hallmark of PD in humans. 
1.4.1.3 Rotenone and paraquat 
Chronic exposure to pesticides is a known risk factor of PD, which has led to numerous 
studies on agricultural pesticides and neurodegeneration, and to the discoveries of 
additional toxin-induced animal models of PD. Chronic systemic injections of the pesticide 
rotenone induces Parkinsonism in rats by entering dopaminergic neurons in a DAT-
independent manner and inhibiting mitochondrial complex I (Betarbet et al., 2000). 
Inhibition of complex I leads to the formation of ROS (Seaton et al., 1997), and 
subsequently to selective nigrostriatal dopaminergic degeneration with a relative sparing of 
VTA neurons, and, notably, cytoplasmic inclusions reminiscent of Lewy bodies (Betarbet et 
al., 2000). Weaknesses of the rotenone model include a high level of variability in the 
individual response to rotenone injections making the lesions hard to standardize, and a 
high risk of mortality due to heart, liver, kidney and gastrointestinal toxicity (Blandini and 
Armentero, 2012). Moreover, due to its high specificity to dopaminergic neurons, rotenone 
treatment fails to recapitulate pathological changes outside the dopaminergic system 
associated with PD (Blandini and Armentero, 2012). 
The herbicide paraquat, which is structurally similar to MPP+, is also used as a systemic 
model of PD. Unlike MPTP and rotenone, paraquat does not pass the blood-brain barrier. 
Instead, paraquat may enter the brain via amino acid transporters (Blandini and Armentero, 
2012), and dopaminergic neurons via DAT (Rappold et al., 2011). Inside the neuron 
paraquat can undergo redox cycling which yields the free radical superoxide, subsequently 
inducing oxidative stress-mediated neurotoxicity (Rappold et al., 2011). As opposed to 
MPP+ and rotenone, paraquat has a low affinity to complex I, thus complex I does not 
appear to be part of its neurotoxic mechanism (Blandini and Armentero, 2012). 
  23 
1.4.2 Genetic models of Parkinson’s disease  
About 95% of PD cases are sporadic, or without any genetic linkage (Dauer and Przedborski, 
2003). Nevertheless, the recent discovery of different genetic mutations, including SNCA 
(the gene encoding α-synuclein), LRRK2, PARK2, PARK7 and PINK1, has led to the 
development of genetic models of PD (Dawson et al., 2010). There is also support for a role 
of dysfunctional transcription factors in PD. Several developmental transcription factors, 
including Nurr1 and Lmx1b, remain expressed in mature dopaminergic neurons, where they 
play a role in the neuronal maintenance. Nucleotide polymorphisms in genes encoding these 
transcription factors have been associated with PD in humans (Bergman et al., 2010, 2009; 
Grimes et al., 2006; Haubenberger et al., 2011; Tang et al., 2012; Xu et al., 2002; Zheng et 
al., 2003), making them promising experimental targets and useful for generating models of 
construct validity. 
1.4.2.1 The cNurr1DATCreER mouse model 
Nurr1, also known as NR4A2, is a developmental transcription factor predominantly 
expressed in the brain (Law et al., 1992; Zetterström et al., 1996), which continues to be 
expressed in mature dopaminergic neurons of the midbrain. Nurr1 is a nuclear receptor 
required for the differentiation and maintenance of functional mDA neurons of the ventral 
midbrain (Castillo et al., 1998; Kadkhodaei et al., 2009; Perlmann and Wallén-Mackenzie, 
2004; Saucedo-Cardenas et al., 1998; Wang et al., 2003; Zetterström et al., 1997). The 
expression of Nurr1, however, is gradually decreased upon ageing (Chu et al., 2002). 
Analyses of postmortem brain tissue revealed down-regulation of Nurr1 in neurons 
containing α-synuclein inclusions in PD patients compared with healthy age-matched 
controls (Chu et al., 2006). Nurr1 expression levels were also decreased in peripheral blood 
lymphocytes in patients with PD compared with age-matched controls (Liu et al., 2012). The 
Nurr1
DATCreER
 mouse model, where Nurr1 is ablated in young adult animals, is characterized 
by a slowly developing mDA neuron dysfunction culminating in loss of cell integrity and 
cellular abnormalities that resemble key aspects of the disease progression of PD 
(Kadkhodaei et al., 2013, 2009). This includes reduced expression of dopaminergic markers 
including TH, DAT and VMAT throughout the nigrostriatal and mesocorticolimbic pathways 
(Kadkhodaei et al., 2013). Nurr1 is also involved in the expression of receptor tyrosine kinase 
RET (Decressac et al., 2012), the receptor for glial cell line-neurotrophic factor (GDNF) 
which has neuroprotective effects in neurotoxin-induced models of PD (Aron and Klein, 
2011; Björklund et al., 2000; Kirik et al., 2004; Kordower, 2000; Ramaswamy et al., 2009). 
As revealed in study I of this thesis, Nurr1 is also involved in the expression of nuclear-
encoded mitochondrial genes (Kadkhodaei et al., 2013), which is consistent with 
mitochondrial dysfunction being proposed as a leading cause of dopaminergic degeneration 
in PD (Dawson and Dawson, 2003). Interestingly, the novel Nurr1 agonist SA00025 was 
recently shown to have both neuroprotective and anti-inflammatory effects in a 
neuroinflammation-exacerbated 6-OHDA lesioned rat model of PD (Smith et al., 2015). 
1.4.2.2 The Lmx1a/b mouse model  
In addition to the cNurr1
DATCreER
 mouse model, the less well characterized Lmx1a/b KO 
mouse model, which harbours a germline deletion of the developmental transcription factors 
Lmx1a and b, has been characterized in study III. Lmx1a and Lmx1b are two highly related 
LIM homeodomain transcription factors essential for the development of mDA neurons 
(Deng et al., 2011; Yan et al., 2011). Under normal development, Lmx1a cooperates with 
Lmx1b to regulate proliferation, specification and differentiation of neuronal stem cells into 
mDA neurons (Yan et al., 2011), and they continue to be expressed also in postmitotic 
differentiating mDA neurons.  Lmx1a is vital for the differentiation of mDA neurons, 
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whereas Lmx1b also appears to be required for the survival of these neurons, and is co-
expressed with TH and paired-like homeodomain transcription factor 3 (Pitx3), a marker 
for mDA neurons (Alavian et al., 2014). Combined null mutations in Lmx1a and Lmx1b 
have previously been shown to result in disrupted Wnt1 signaling, decreased proliferation 
of progenitor cells and decreased neurogenesis, ultimately resulting in abolished generation 
of mDA neurons (Deng et al., 2011; Yan et al., 2011). However, the exact function of 
Lmx1a and Lmx1b after specifying dividing neural progenitors has remained unknown. 
Interestingly, genetic variants in the LMX1A and LMX1B genes have been linked to an 
increased risk of developing PD in humans (Bergman et al., 2009). In study III we explored 
the role of Lmx1a/b in adult neurons with a focus on PD pathology and symptomatology, 
revealing that Lmx1a/b ablation induced a phenotype strikingly similar to early PD. 
1.4.2.3 α-synuclein overexpressing models 
α-synuclein is a major constituent of Lewy bodies, as discussed in detail in 1.3.1. α-synuclein 
can induce PD when mutated, or when the WT form is increased by gene duplication or 
triplication (Douglas et al., 2007). One problem with transgenic overexpression of α-
synuclein is that α-synuclein pathology is very widespread in PD. A successful PD model 
must mimic this broad pathological distribution; thus, the phenotype of these models depends 
to a great extent on the promoter used to drive transgene expression (Chesselet, 2008). 
Notably, transgenic α-synuclein overexpressing mouse models do not exhibit any progressive 
loss of dopaminergic neurons, but present with several functional abnormalities of the 
nigrostriatal system (Dawson et al., 2010; Giráldez-Pérez et al., 2014). Aggregated α-
synuclein appears to induce toxic effects by impairing mitochondrial functions and by 
impairing proteasomal and lysosomal systems. The most promising transgenic α-synuclein 
overexpressing mouse model, which overexpresses human A53T mutated α-synuclein under 
the mouse prion promoter, exhibits age-dependent neurodegeneration (Chesselet, 2008) and 
mitochondrial dysfunctions, including damaged mitochondrial DNA and mitochondrial 
degeneration, highlighting a relationship between α-synuclein and mitochondrial functions 
(Martin et al., 2006).  
An alternative to the transgenic approach is to use stereotaxic injections of viral vectors to 
overexpress α-synuclein in specific sets of neurons to induce a PD-like pathology. α -
synuclein overexpression in neurons of the substantia nigra induced by this approach result in 
axonal pathologies and progressive cell loss (Kirik et al., 2002; Klein et al., 2002; Lo Bianco 
et al., 2004). In rats, intranigral α-synuclein overexpression induced by AAV vectors led to 
the development of motor impairments and a prominent loss of dopaminergic neurons in the 
SNc, but not in the VTA, although signs of α-synuclein toxicity was found also in the latter 
area (Ulusoy et al., 2010). This bears resemblance to the VTA being less susceptible to 
neurodegeneration in patients with PD. In study IV we used AAV vectors to overexpress α-
synuclein specifically in the VTA to study the impact on PD-related symptoms. 
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2 AIMS 
Valid animal models are key to understand the pathophysiological processes in neurological 
and psychiatric disorders. The overall aim of this thesis was to characterize and validate 
genetically induced progressive models of Parkinson’s disease to improve understanding of 
how pathophysiological mechanisms contribute to the symptomatology and pathology of 
Parkinson’s disease. We were specifically interested in the role of developmental 
transcription factors in behavioural functions and neurotransmitter release. We also focused 
on the evaluation of a potential therapeutic role of TAAR1 in the treatment of Parkinson’s 
disease, using both neurotoxin-induced and a newly characterized genetically induced model. 
The specific aims of this thesis included: 
1. Characterization of the cNurr1DATCreER mouse line to determine whether this model 
recapitulated features of Parkinson’s disease.  
2. Investigation of the role of TAAR1 in L-DOPA responsivity and glutamate release 
using models of Parkinson’s disease, including 6-OHDA lesioned mice and 
cNurr1
DATCreER
 KO mice. 
3. Characterization of the Lmx1a/bDATCre mouse line to determine whether this model 
recapitulated features of Parkinson’s disease.  
4. Investigation of the role of α-synuclein overexpression in the VTA in the 
symptomatology of Parkinson’s disease. 
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3 MATERIALS AND METHODS 
 
EXPERIMENTAL MODELS 
cNurr1
DATCreER
 KO mice (I, II) 
TAAR1 KO mice (II) 
Lmx1a/b
DATCre
 KO mice (III) 
6-OHDA lesioned mice (II) 
α-synuclein overexpressing Sprague-Dawley rats (IV) 
BEHAVIOURAL METHODS 
Motor functions 
Open field test (I, III)  
Ledged beam test (I, II, III)  
Pole test (I, II, III)  
Cylinder test (II)  
Rotation test (II) 
Learning and memory functions 
Passive avoidance (III, IV)  
Novel object recognition (III)  
T-maze (III) 
Anxiety-like behaviour 
Elevated plus maze (III) 
Depressive-like behavior 
Porsolt swim test (III) 
Sucrose preference test (III) 
PHARMACOLOGICAL TREATMENTS 
Acute and chronic systemic administration (I, II)  
Tamoxifen treatment (I, II)  
Local brain administration (II) 
STEREOTACTIC TECHNIQUES 
In vivo amperometry (II)  
6-OHDA lesioning (II)  
Adeno-associated viral vectors (IV)  
Methylene Blue intracranial infusion (II) 
HISTOLOGY 
Autoradiography (II) 
Nuclear Fast Red counterstaining (II) 
BIOCHEMICAL TECHNIQUES 
Immunoblotting (II) 
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3.1 PHARMACOLOGICAL COMPOUNDS USED IN THE PRESENT WORK 
 
NAME FUNCTION 
L-DOPA Dopamine precursor 
Ropinirole Selective dopamine D2-like receptor agonist (D3 > D2 > D4) 
Apomorphine Non-selective dopamine agonist 
RO5166017 Selective TAAR1 agonist 
EPPTB Selective TAAR1 antagonist 
AM251 Inverse CB1 cannabinoid receptor agonist 
Tamoxifen Estrogen receptor antagonist 
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3.2 GENERAL BEHAVIOURAL PROTOCOLS USED IN THE PRESENT WORK 
 
 
 
Figure 3.2.1 Tests of motor functions in the pole test and beam traversal tests. (A) In 
the pole test, mice are placed head-up on top of a vertical pole (diameter: 8 mm, height: 55 
cm) and trained for 1 day to turn and descend the pole back into their home cage. On the 
day of the test, animals perform 3 trials and the time to orient downward, called t-turn (1), 
and the total time to turn and descend the pole, called t-total (2), are measured at a 
maximum duration of 120 seconds. (B) In the beam traversal test, mice are trained for two 
consecutive days to traverse a beam leading to their home cage. On the test day, a grid (1 
cm2) of corresponding width is placed 1 cm above the beam and the mice are videotaped 
while traversing it. The time to walk across the beam, the number of steps and errors 
(defined as a limb slipping through the grid) are calculated. 
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Figure 3.2.2 Tests of cognitive skills. (A) The T-maze is a test of working memory. A 
spontaneous alternation paradigm was used in this thesis, based on the natural tendency of 
rodents to alternate between opposite goal arms during natural exploration. This paradigm 
has the advantage that it does not require any training or food rewards. Each test starts with 
a forced trial followed by 14 choice trials. After each completed arm choice the mouse is 
placed back into the start arm and confined for 5 seconds before each new consecutive trial. 
One point is assigned for each choice arm alternation. (B) The novel object recognition test 
is a test of object memory, and is useful for evaluating short-term memory in mice. A 
habituation session is performed in an empty open field arena to let the animals habituate to 
the test environment. 24 h after the habituation phase, the mice are allowed to explore the 
open field arena for 5 minutes in the presence of two identical objects. The memory test (5-
10 minutes) is performed 1-4 hours after the training session, during which one of the 
previous familiar objects is replaced with a novel object. Object exploration time (typically 
defined as nose < 1 cm from object) can be measured manually or automatically using a 
tracking software connected to a ceiling mounted camera. A relative discrimination index is 
calculated as (TimeNovel-TimeFamiliar)/(TimeNovel+TimeFamiliar) based on the exploratory time 
of each object, and a significant preference for the novel object indicates intact object 
memory. (C) The passive avoidance test is used to assess emotional contextual memory. 
The apparatus consists of two compartments connected via an automatic door: one brightly 
illuminated with white walls, and one with black walls covered by a ceiling. During the test 
session the mouse is placed in the bright compartment and the step-through latency into the 
dark compartment is measured. Once the mouse enters the dark compartment with all four 
paws the automatic door is closed and a current is delivered through the grid floor (0.3 mA) 
for 2 seconds. 30 seconds after step-through the mouse is removed and placed into its home 
cage. The test session (9 minutes, no current) is typically performed 24 hours after the 
training session. The mouse is then placed back into the bright compartment and the step-
through latency to enter into the dark compartment is measured. A significantly prolonged 
step-through latency during the test session indicates intact emotional contextual memory.   
  
 30 
 
Figure 3.2.3 Tests of anxiety- and depressive-like behaviour. (A) The Porsolt swim test 
is based on behavioral despair, measured as inactive floating after initial swimming or 
climbing. This test is sensitive to acute antidepressant treatment, which increases the time 
spent swimming and climbing. Each test session lasts for 5-6 minutes (water temperature: 
23-25°C) and is typically videotaped for subsequent analysis. (B) The sucrose preference or 
sucrose consumption test is a measure of anhedonia, based on the preference of a sucrose 
solution over water. Two bottles, one containing the sucrose solution and one containing tap 
water, are presented for 3 consecutive days, positions interchanged each day. Sucrose 
preference is calculated as a percentage of the total volume consumed. (C) The elevated 
plus maze is used to assess anxiety-like behavior. The apparatus consists of four arms 
elevated one meter above the ground, two with high walls and two without walls. Rodents, 
being prey animals, naturally prefer the closed arms and avoid the open arms. During 
testing, each animal is individually placed in the center of the apparatus and allowed to 
explore it for 5 minutes. The number of entries into the open and closed arms and the total 
time spent in each pair of arms are measured and compared. (D) Thigmotaxis behavior in 
an open field arena, defined as the animal staying in close proximity of the walls, can be 
used as a measure of anxiety since rodents tend to avoid bright, open areas depending on 
the level of anxiety. 
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3.3 IN VIVO AMPEROMETRY  
 
 
 
Figure 3.3.1 Schematic drawing of a microelectrode array (MEA) of the S2 model 
used for in vivo glutamate recordings. Each MEA has four platinum electrode sites (15 x 
333 μm) organized as pairs. Prior to experiments two platinum sites are coated with 
glutamate oxidase (GluOx), which cause enzymatic breakdown of glutamate into α-
ketoglutarate and peroxide (H2O2), whereas the second pair of sites are coated with an 
inactive protein matrix (BSA) and used for self-referencing. All four sites are coated with a 
protective layer of metaPhenylene-diamine dihydrochloride (mPD) to block interferents 
such as dopamine, DOPAC and ascorbic acid. Peroxide is oxidized at the platinum site, 
resulting in the release of two electrons that create a current measured by a Fast Analytical 
Sensing Technology (FAST 16-mkII) system. Responses recorded at the reference sites are 
subtracted from those generated at the recording sites during analysis, with the resulting 
signal representing glutamate measurements. A micropipette is aligned between the four 
sites and used for local delivery of 70 mM KCl and the compound of interest to stimulate 
depolarization and evoke glutamate release. 
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Figure 3.3.2 In vitro calibration of MEA. Before each experiment, electrodes are 
calibrated in vitro to determine the selectivity and sensitivity for glutamate against ascorbic 
acid. Electrodes are suspended in 0.05 M phosphate-buffered saline (pH 7.4, 37°C), and 
analytes of interest are added to the buffer to determine the response, detected as a change 
in current. The electrode sites coated with GluOx should respond to glutamate and the 
reporter molecule H2O2, but not to the interferents ascorbic acid (AA) and dopamine (DA), 
which are repelled by the mPD coating. The electrode sites with no GluOx coating should 
respond only to molecules not repelled by mPD and are used for self-referencing. Only 
electrodes that fulfill certain calibration criterions based on their selectivity and sensitivity 
for L-glutamate are selected for in vivo experiments. 
 
 
Figure 3.3.3 In vivo recording. The 
arrows indicate KCl ejections, which are 
typically made for 1 second at 1-minute 
intervals during experiments.  
Compounds of interest can be mixed 
with KCl for local delivery. KCL 
ejections are followed by increased 
concentration of glutamate at the 
recording channels. During analysis, the 
signal recorded at the reference channels 
is subtracted from that of the recording 
channels to remove background noise. 
The graph shows a striatal recording 
from a cNurr1
DATCreER
 KO mouse 
superimposed on that of a WT mouse. 
Data from these experiments are 
presented in study II. 
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4 RESULTS AND DISCUSSION 
The constituent studies focus on the characterization of models of experimental 
Parkinsonism, and on the utilization of these models to identify disease mechanisms related 
to Parkinson’s disease. Below is a brief summary of the thesis work, including some relevant 
unpublished findings. More comprehensive descriptions are found in the full papers. 
4.1 AIM I: CHARACTERIZATION OF THE TRANSGENIC cNURR1DATCreER 
MOUSE MODEL 
The transcription factor Nurr1 has been associated with PD in humans and is essential for the 
development of ventral midbrain dopamine neurons. Paper I aimed at investigating the role of 
Nurr1 in adult dopaminergic neurons, focusing on factors relevant for PD. Conditional Nurr1 
gene targeted mice, in which Nurr1 was ablated selectively in mature dopaminergic neurons 
by tamoxifen treatment (cNurr1
DTACreER
 KO mice), were used. Immunostaining was 
performed to detect Nurr1, dopaminergic markers and cell integrity in developing and mature 
neurons of the ventral midbrain and striatum. High-pressure liquid chromatography was 
performed in dissected brain tissue of the 
striatum and ventral midbrain to detect 
dopamine and its metabolites. Laser-
microdissected dopaminergic neurons were 
used for RNA extraction and next-
generation mRNA sequencing to identify 
Nurr1-regulated genes. Behavioural 
analyses focusing on motor functions were 
performed to assess the behavioural 
phenotype. These experiments revealed that 
Nurr1 ablation resulted in a progressive 
pathology associated with reduced striatal 
dopamine, impaired motor behaviours 
(Figures 4.1A and B), and dystrophic axons 
and dendrites, and that Nurr1 regulates a 
battery of genes expressed in dopaminergic 
neurons, including nuclear-encoded 
mitochondrial genes. These experiments 
indicate that Nurr1 has a key function in 
sustaining the high respiratory levels in 
dopaminergic neurons, and that Nurr1 
ablation in mice recapitulates early features 
of PD disease. Based on the findings in 
Paper I, the cNurr1
DTACreER
 KO mouse 
model was found to hold promise as a valid 
model of progressive PD, and subsequent 
experiments are currently performed to 
further characterize this model with a focus 
on non-motor functions in PD.  
Fig 4.1. Open-field behavior in adult and old cNurr1DATCreER KO 
and WT mice. (A) Both adult and old cNurr1DATCreER KO mice 
moved a significantly shorter distance in an open field arena 
compared with age-matched WT mice. (B) Adult, but not old, 
cNurr1DATCreER KO mice performed fewer rearings compared 
with age-matched WT mice. 
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Figure 4.2.1 In vivo amperometry in striatum 
of 6-OHDA lesioned mice. Two superimposed in 
vivo amperometry L-glutamate recordings from one 
intact and one 6-OHDA lesioned hemisphere, showing 
enhanced glutamate amplitudes in the lesioned 
striatum (black trace).  
  
4.2 AIM II: THE ROLE OF TAAR1 IN L-DOPA RESPONSIVITY AND 
GLUTAMATE RELEASE IN MODELS OF PARKINSON’S DISEASE
  
As discussed in detail in 1.3.3.2, TAAR1 is a recently discovered receptor that modulates 
dopaminergic transmission. Paper II aimed at investigating the influence of TAAR1 on 
factors related to PD, including L-DOPA-induced sensitization and corticostriatal glutamate 
release, using pharmacological interventions, Parkinsonian mouse models and TAAR1 KO 
mice. Mice with unilateral medial forebrain bundle 6-OHDA lesions were used to model L-
DOPA sensitization following subchronic L-DOPA treatment. Mice with intrastriatal 6-
OHDA lesions and the previously characterized cNurr1
DATCreER 
KO mouse model were used 
to model progressive dopaminergic neurodegeneration. Presynaptic glutamate release was 
measured by in vivo amperometry (described in 3.3), whereas postsynaptic glutamate 
transmission was detected by immunoblotting for phosphorylation of AMPA-receptor 
subunits. These experiments revealed that TAAR1 KO mice had higher levels of the 
dopaminergic markers TH and DAT than WT mice, and were less vulnerable to intrastriatal 
6-OHDA injections. TAAR1 KO mice sustaining medial forebrain bundle 6-OHDA lesions 
were more markedly supersensitive to subchronic L-DOPA treatment both in terms of 
rotations, abnormal involuntary movements and AMPA receptor phosphorylation compared 
with WT mice. Conversely, pretreatment with the TAAR1 agonist RO5166017 reduced 
supersensitization to L-DOPA in 6-OHDA-treated WT mice, in parallel with a reduction in 
L-DOPA-induced AMPA receptor phosphorylation. Corticostriatal glutamate release was 
enhanced both in the lesioned hemisphere 
of 6-OHDA-treated mice (Figures 4.2.1 
and 4.2.2) and in cNurr1
DATCreER
 KO mice 
compared with respective controls (Figure 
4.2.2), whereas nigral glutamate release 
remained unaltered in the Parkinsonian 
state of both models (Figure 4.2.3). These 
findings highlight similarities between 
these two experimental models with respect 
to both striatal and nigral glutamate release. 
In cNurr1
DATCreER
 KO mice, the enhanced 
corticostriatal glutamatergic transmission 
was reversed by the TAAR1 agonist and by 
the D2-like receptor agonist ropinirole via a 
CB1 receptor dependent mechanism (Figure 
4.2.4). These data reveal that TAAR1 
modulates behavioral responses to L-
DOPA, and regulates pre- and postsynaptic 
glutamate neurotransmission in the striatum 
(Figure 4.2.5).    
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Figure 4.2.2 Striatal glutamate 
release in two models of PD. 
Striatal glutamate release was enhanced in 
the Parkinsonian state, i.e. in the lesioned 
hemisphere of 6-OHDA lesioned mice (A), 
and in cNurr1
DATCreER
 KO mice (B), 
highlighting similarities between these two 
models. Statistics: Two-way ANOVA 
followed by Fisher’s LSD post hoc test, 
*p<0.05; **p<0.01; ***p<0.001 
 
Figure 4.2.3  Glutamatergic 
neurotransmission in SNc in 
two models of PD. No changes in 
glutamate amplitudes (A), tonic 
glutamate levels (B) or the glutamate 
reuptake rate (T80) (C) were found in 
SNc of 6-OHDA lesioned mice. 
Similarly, no changes in glutamate 
amplitudes (D), tonic glutamate levels 
(E) or the glutamate reuptake rate (F) 
were found in SNc of Nurr1
DATCreER
 KO 
mice compared with WT mice. This 
indicates that excitotoxic glutamate 
release in SNc plays little role in these 
two models.  
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Figure 4.2.4 Pharmacological  
modulation of striatal glutamate release.  
The enhanced glutamate release in cNurr1
DATCreER
 KO 
mice was inhibited by local administration of D2 receptor 
agonist ropinirole (100 μM). Blockade of CB1 receptors 
by AM251 did not affect striatal glutamate release, but 
attenuated ropinirole’s effect. This supports previous data 
showing that D2 receptors attenuate dysfunctional 
glutamate release via a mechanism involving CB1 
receptors, possibly via retrograde endocannabinoid 
signaling. The TAAR1 antagonist EPPTB (10 nM) did not 
affect corticostriatal glutamate release or the effect of 
ropinirole. The TAAR1 agonist RO5166017 (500 nM) 
inhibited enhanced glutamate release. Blockade of CB1 
receptors by AM251 attenuated the effect of RO5166017.  
No effects were seen in WT animals. This suggests that 
local TAAR1 agonism, via CB1 receptors, mediates a 
rapid attenuating effect on the hyperglutamatergic state in 
experimental PD. Statistics: One-way ANOVA followed 
by Fisher’s LSD post hoc test, *p<0.05; **p<0.01; 
***p<0.001 vs. KO veh;
 #
p<0.05; 
##
p<0.01 vs. KO 
ropinirole. 
 
Figure 4.2.5 Potential modulation of corticostriatal glutamate release by TAAR1. A simplified 
schematic drawing of a corticostriatal synapse and the possible expression of TAAR1 relevant for interactions with the 
dopaminergic system and the modulation of glutamate release. TAAR1 (green) may be located in a position to modulate 
corticostriatal glutamate release by interacting with DAT at dopaminergic terminals of the SNc, by interacting with D2 
receptors (red) at dopaminergic or glutamatergic terminals, or at MSN of the indirect pathway. TAAR1 may affect glutamate 
release indirectly by enhancing dopamine release from nigrostriatal terminals, thus enhancing activation of postsynaptic D2 
receptors similarly to ropinirole. This effect would be abolished by blockade of CB1 receptors. CB1R: cannabinoid receptor 
type 1; DA: dopamine; eCB: endocannabinoids, Glu: glutamate; mGluR: metabotropic glutamate receptor.  
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4.3 AIM III: BEHAVIOURAL CHARACTERIZATION OF THE cLMX1A/BDATCre 
TRANSGENIC MOUSE MODEL  
 
Paper III focused on the roles of the developmental transcription factors Lmx1a and Lmx1b 
in the maintenance of neuronal properties of relevance for neuropathological conditions, 
particularly PD. Lmx1a and Lmx1b are two highly related LIM homeobox transcription 
factors required for the early specification of neuronal stem cells into ventral mDA neurons. 
The function of Lmx1a and Lmx1b in maturing and adult mDA neurons was investigated 
by analysing the consequences of mDA neuron-specific ablation in conditional knockout 
mice using histology, in situ hybridization, stereological cell counting, behavioural tests, 
electrophysiology, high-performance liquid chromatography, electron microscopy, and 
immunoblotting. The cLmx1a/bDATCre mouse model used in these experiments harboured 
floxed LMX1A and LMX1B and a cre recombinase expressed under DAT, which starts to 
be expressed at embryonic day 13.5. Immunostaining of Lmx1b was also performed in 
human postmortem tissue from healthy subjects and patients with PD. This study revealed 
that conditional ablation of Lmx1a/b after mDA neuron specification resulted in 
abnormalities that resemble early features of PD. Expression of Lmx1a was rapidly 
decreased at postnatal stages, whereas Lmx1b remained continuously expressed throughout 
life. Electron micrographs revealed an abnormal morphology of dopaminergic nerve 
terminals following Lmx1a/b ablation, characterized by giant nerve terminals and an 
accumulation of autophagosomes and endosome-like structures in the axoplasm. Lmx1b 
expression was shown to be decreased in neuromelanin-positive neurons in postmortem 
brain tissue from PD patients. A battery of behavioural tests was performed in adult mice 
(6-9 months of age) and old mice (18-21 months of age). A summary of the behavioural 
phenotype is shown in Figure 4.3. The behavioural test battery revealed that both adult and 
old animals were impaired in the wooden block test (Figure 4.3A), a test of social olfactory 
functions. Both adult and old animals also required longer time to complete the pole test 
compared with WT animals (Figures 3.2.1A and 4.3D), whereas old animals required a 
longer time to complete the beam traversal test (Figure 3.2.1B), indicating a presence of 
progressive motor impairments. Adult animals were also impaired in the novel object 
recognition test (Figures 3.2.2B and 4.3B), indicating a mild cognitive phenotype emerging 
early in the pathology, likely related to pathological changes in the prefrontal cortex and 
striatum as detected in adult animals. No alterations in exploratory behaviour were revealed 
in the novel object recognition or open field tests (Figure 4.3C and E). Both working 
memory and long-term memory functions, assessed using the T-maze (Figure 3.2.2A) and 
passive avoidance tests (Figure 3.2.2C), remained intact in Lmx1a/bDATCre KO mice at both 
age intervals. No depressive- or anxiety-like behaviours were found in Lmx1a/bDATCre KO 
mice using the Porsolt swim test (Figure 3.2.3A), sucrose preference test (3.2.3B), elevated 
plus maze (3.2.3C) or by assessing thigmotaxis in the open-field test (Figures 3.2.3D and 
4.3F). This suggests that genetic ablation of Lmx1a/b does not induce any emotional 
behaviour, and although a significant loss of TH was found in the VTA in old animals, this 
lack of emotional phenotype suggests that there were no major alterations in the 
serotonergic and noradrenergic neurotransmitter systems. These findings indicate that 
Lmx1a/b-ablation in dopaminergic neurons lead to impaired motor functions, impaired 
short-term memory and impaired olfaction in adult animals. Lmx1a/b was also required for 
the normal execution of the autophagic-lysosomal pathway, for the integrity of 
dopaminergic nerve terminals and for long-term mDA neuronal survival. In conclusion, the 
results of this study reveal that Lmx1b is required for the function of mature midbrain mDA 
neurons, and that this model recapitulates several features of PD in humans. Lmx1b may 
thus be associated with the pathogenesis of PD, likely via its role in the autophagic-
lysosomal pathway. 
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Figure 4.3 Summary of the behavioural phenotype of adult WT and Lmx1a/bDATCre KO animals, 
revealing olfactory, cognitive and motor impairments, but intact exploratory behaviour. (A) The 
wooden block test revealed a significantly decreased preference for the novel smell of an unknown animal 
compared to the animal’s own smell in Lmx1a/bDATCre KO animals. (B) Lmx1a/bDATCre KO animals did not 
prefer a novel object before a familiar one, seen as a discrimination index close to 0, whereas WT animals 
prefered the novel object. (C) There was no difference between the genotypes in the total time spent 
exploring the object pair during the training phase, indicating that the poor performance of Lmx1a/b
DATCre
 
KO animals was not related to altered exploratory behaviour. (D) Lmx1a/b
DATCre
 KO animals required a 
longer time to turn and climb down during the pole test compared with WT animals, indicating impairments 
of posture and fine motor skills. (E) The total distance travelled and (F) the time spent in the thigmotaxis 
zone did not differ between the genotypes in the open field test, indicating intact exploratory behaviour and 
lack of anxiety-like behaviour in Lmx1a/b
DATCre
 KO animals. The open field test is an important control 
measure, since most behavioural tests are affected by the basal level of exploratory behaviour. 
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4.4 AIM IV: THE ROLE OF α-SYNUCLEIN OVEREXPRESSION IN THE VTA IN 
THE SYMPTOMATOLOGY OF PARKINSON’S DISEASE 
The accumulation of Lewy bodies, misfolded protein aggregates containing the misfolded 
protein α-synuclein, is a major pathological hallmark of PD. However, neurodegeneration in 
PD is not restricted to the substantia nigra, but also affects the VTA, where α-synuclein 
aggregates are also found in early stages of the disease. The VTA mainly projects to the 
frontal cortex, the ventral striatum, amygdala and the hippocampus, and degeneration of these 
projections are thought to play a role in the cognitive and emotional symptoms of PD. Lewy 
body accumulation in the VTA correlates with the onset of cognitive impairments, but the 
impact of the VTA in the symptomatology of PD remains elusive. In study IV, we 
overexpressed α-synuclein specifically in the VTA using AAV vector constructs in order to 
evaluate the pathological impact on motor- and non-motor symptoms across time. 
Immunohistochemical stainings were performed to assess neuropathological features. The 
ledged beam test, described in Figure 3.2.1A, was used to monitor motor functions, and the 
step-through passive avoidance test was used to evaluate emotional contextual memory 
functions. Step-through passive avoidance is a paradigm based on Pavlovian fear 
conditioning, and is described in Figure 3.2.2C. Being prey animals and nocturnal, rodents 
naturally prefer dark areas over brightly illuminated ones. By coupling a preferred dark 
compartment (the conditioned stimulus) with an aversive stimulus (the unconditioned 
stimulus), in this case a weak electric current, the animal can be taught to prefer the light 
compartment, i.e. to display passive avoidance of the dark compartment. Fear learning is 
dependent on the amygdala (Phillips et al., 2010) and prefrontal cortex (Abercrombie et al., 
1989; Gonzalez et al., 2014), whereas the hippocampus is involved in complex memory 
functions, including the mental representation of complex environments (Baarendse et al., 
2008; Kim and Fanselow, 1992; Morris et al., 1982; Selden et al., 1991), but not in basic 
associative functions (Schmaltz and Theios, 1972; Solomon, 1977; Winocur et al., 1987). 
 
Figure 4.4 Passive avoidance performance in GFP and α-synuclein overexpressing rats 3 
and 8 weeks following AAV injection. (A) 3 weeks after AAV injection only AAV-GFP injected 
animals learned the passive avoidance task, indicated as an enhanced step-through latency during the PA test 
phase compared with during the training phase. The AAV-GFP group also displayed a significantly prolonged 
step-through latency during the passive avoidance test phase compared with the AAV-α-synuclein group. (B) 
Upon re-exposure to the passive avoidance test 8 weeks following vector injection both groups learned the task. 
However, the step-through latency was still significantly prolonged in the AAV-GFP injected group compared 
with the AAV-α-synuclein group, indicating a better memory performance in this group. Two-way ANOVA 
followed by Fisher’s LSD post hoc test, *p<0.05; ***p<0.001 
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Thus, the association of a unisensory cue with a fear response is mediated by the 
hippocampus when this cue is presented in a complex environment, making the passive 
avoidance task a measure of hippocampus-dependent contextual and emotional memory. 
Thus, the retention performance, i.e. the time it takes before the rodent enters the dark 
compartment again during the passive avoidance retention test, is a measure of emotional 
memory, and is sensitive to changes in serotonergic, glutamatergic and cholinergic 
neurotransmission (Madjid et al., 2006; Ogren, 1985). The Porsolt swim test, elevated plus 
maze and sucrose preference tests were performed to investigate depressive-like and anxiety-
like behavior. 
These experiments demonstrated that α-synuclein overexpression in dopaminergic neurons of 
the VTA induced a reduced number of TH+ neurons in the VTA, but not in the substantia 
nigra, 8 weeks after AAV-α-synuclein vector injection. Motor deficits appeared 3 weeks 
following AAV-α-synuclein vector injection and were limited to an increased number of 
stepping errors when crossing a beam, progressing in severity across time. Emotional 
memory impairments were revealed in the passive avoidance test 8 weeks following AAV-α-
synuclein vector injection (Figure 4.4). However, no depressive- or anxiety-like behavior was 
found. These findings indicate that Lewy body accumulation in the VTA may play a role in 
some motor impairments related to body control, and in cognitive impairments related to 
emotional contextual memory.   
4.5 GENERAL CONCLUSIONS 
The theme of this thesis has been novel means to induce various aspects of PD in 
experimental animals to provide a deeper understanding of the disease processes and how it 
interacts with the symptomatology of PD. In conclusion, this work has revealed how both 
pathological and behavioural features related to early PD can be induced by ablation of the 
developmental transcription factors Nurr1 and Lmx1a/b, previously known to play elusive 
roles in adult dopaminergic neurons and PD in humans. Using the cNurr1
DATCreER
 KO model 
as a bilateral model of early PD, we also unveiled a potential role of TAAR1 in experimental 
PD. However, future studies will be warranted to understand the complex modulatory and 
sometimes discrepant properties of TAAR1 in Parkinsonian states. Finally, overexpression of 
α-synuclein in VTA was shown to induce cognitive and mild motor impairments paralleled 
by a loss of dopaminergic neuron integrity restricted to the VTA, but no anxiety- or 
depressive-like behavior, suggesting a role of α-synuclein aggregation in the VTA in the 
cognitive symptoms of PD. Hopefully these data will contribute to a better understanding of 
the early pathological disease stages, to improved experimental models and ultimately to 
better treatment regiments in PD. 
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